_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
502568356,7/12/2014 07:16:38,,1321246384,7/12/2014 07:15:48,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,"Ductal carcinoma in situ (DCIS) MICROCALCIFICATION on mammography,",0-7-17-20-25-53-72-75,0-7-17-20-25-53-72-75,"DUCTAL CARCINOMA IN SITU (DCIS) microcalcification on mammography,","Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 07:33:54,,1321252421,7/12/2014 07:33:28,elite,1,28322695,GBR,G8,Dewsbury,217.44.206.25,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,MICROCALCIFICATION,53,0-7-17-20-25,DUCTAL CARCINOMA IN SITU (DCIS),"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 07:41:21,,1321254441,7/12/2014 07:41:08,listia,1,26989211,USA,VA,Suffolk,24.241.13.101,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,MICROCALCIFICATION,53,0-7-17-20,DUCTAL CARCINOMA IN SITU,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 07:53:20,,1321258178,7/12/2014 07:52:56,prodege,1,27934334,GBR,Q2,Wokingham,86.166.73.224,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,MICROCALCIFICATION,53,0-7-17-20-25,DUCTAL CARCINOMA IN SITU (DCIS),"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 08:17:34,,1321265569,7/12/2014 08:17:31,neodev,1,11598752,CAN,ON,Toronto,216.165.208.242,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,"usually manifests as MICROCALCIFICATION on mammography, but",32-40-50-53-72-75-88,0-7-17-20-32-40,DUCTAL CARCINOMA IN SITU usually manifests,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 08:30:59,,1321270435,7/12/2014 08:30:50,clixsense,1,6355977,NLD,07,Amsterdam,46.129.42.165,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,MICROCALCIFICATION,53,0-7-17-20,DUCTAL CARCINOMA IN SITU,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 08:47:20,,1321275292,7/12/2014 08:47:14,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,"usually manifests as MICROCALCIFICATION on mammography, but several",32-40-50-53-72-75-88-92,0-7-17-20-32-40-53,DUCTAL CARCINOMA IN SITU usually manifests microcalcification,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 08:51:11,,1321276644,7/12/2014 08:50:57,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,Ductal carcinoma MICROCALCIFICATION,0-7-53,0-7-17-20,DUCTAL CARCINOMA IN SITU,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 08:56:06,,1321278200,7/12/2014 08:55:52,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.250,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,MICROCALCIFICATION,53,0-7-17-20,DUCTAL CARCINOMA IN SITU,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568356,7/12/2014 08:58:50,,1321279122,7/12/2014 08:58:24,instagc,1,27770607,USA,TX,El Paso,72.183.244.51,53,0,,,71,24,MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,MICROCALCIFICATION,53,0-7-17-20,DUCTAL CARCINOMA IN SITU,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described.",53,0 7 17 20,53,0,71,24,1,RO-disease_may_have_finding,902812,"Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography, but several other unusual forms of presentation on mammography are also described",microcalcification,Ductal carcinoma in situ
502568357,7/12/2014 07:14:52,,1321245885,7/12/2014 07:14:15,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,12-16-20-23-34-42-3,evaluate the use of PAPAVERINE induced erection,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 07:37:37,,1321253375,7/12/2014 07:37:17,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,23,PAPAVERINE,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 07:43:14,,1321254987,7/12/2014 07:42:49,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,23,PAPAVERINE,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 08:14:40,,1321264799,7/12/2014 08:14:25,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,23-34-42,PAPAVERINE induced erection,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 08:34:44,,1321271585,7/12/2014 08:33:53,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,23,PAPAVERINE,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 08:48:13,,1321275664,7/12/2014 08:48:09,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"test in men with ERECTILE DYSFUNCTION, 24 patients had",72-75-79-84-93-106-109-118-67,12-16-20-23-34-42-51-54,the use of PAPAVERINE induced erection as a,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 08:54:14,,1321277580,7/12/2014 08:53:47,neodev,1,26698025,NLD,05,Kerkrade,84.25.162.122,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,23-34-42,PAPAVERINE induced erection,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 08:54:59,,1321277786,7/12/2014 08:52:02,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,23,PAPAVERINE,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 08:56:54,,1321278505,7/12/2014 08:56:41,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,23,PAPAVERINE,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568357,7/12/2014 09:03:15,,1321280757,7/12/2014 09:03:03,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,84,23,,,104,33,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION,",84-93,23-34-42,PAPAVERINE induced erection,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum.",84 93,23,84,23,104,33,1,RO-may_diagnose,906676,"To evaluate the use of papaverine-induced erection as a diagnostic test in men with erectile dysfunction, 24 patients had papaverine injected into the corpus cavernosum",erectile dysfunction,papaverine
502568358,7/12/2014 07:17:51,,1321246793,7/12/2014 07:17:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,BACTERIUM,65,97-113-121-124-134,epidemiological aspects of WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 07:32:17,,1321251859,7/12/2014 07:31:14,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,BACTERIUM,65,124-134,WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 07:36:34,,1321253154,7/12/2014 07:36:24,prodege,1,6316959,GBR,"","",87.112.13.121,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,BACTERIUM,65,124-134,WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 07:45:49,,1321255752,7/12/2014 07:44:18,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,BACTERIUM,65,124-134,WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 07:47:33,,1321256223,7/12/2014 07:47:11,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,BACTERIUM,65,124-134,WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 07:53:19,,1321258177,7/12/2014 07:52:35,clixsense,1,6500439,AUS,02,Ingleburn,115.146.65.99,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of Whipple's disease.,0-5-8-11-22-27-31-44-57-60-65-75-78-83-86-91-97-113-121-124-134,5-8-11-22-27-31-44-57-60-65-75-78-83-86-91-97-113-121-124-134-0,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 08:18:50,,1321265986,7/12/2014 08:18:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,BACTERIUM,65,124-134,WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 08:21:17,,1321266868,7/12/2014 08:20:47,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,relationship of this BACTERIUM as well as,44-57-60-65-75-78-83,97-113-121-124-134,epidemiological aspects of WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 08:42:49,,1321273930,7/12/2014 08:42:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,BACTERIUM,65,124-134,WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568358,7/12/2014 08:52:25,,1321277031,7/12/2014 08:51:23,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,65,124,,,74,141,BACTERIUM,WHIPPLE'S DISEASE,BACTERIUM,65,124-134,WHIPPLE'S DISEASE.,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease.,65,124 134,65,124,74,141,1,RO-has_causative_agent,903809,This is in accordance with the phylogenetic relationship of this bacterium as well as with known epidemiological aspects of Whipple's disease,bacterium,Whipple's disease
502568359,7/12/2014 07:27:29,,1321250334,7/12/2014 07:26:57,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,treatment of INCREASED BLOOD PRESSURE (BP),107-117-120-130-136-145,28-33-44,well controlled HYPERTENSION,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 07:30:36,,1321251367,7/12/2014 07:30:04,prodege,1.0,6316959,GBR,"","",87.112.13.121,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,INCREASED BLOOD PRESSURE,120-130-136,44,HYPERTENSION,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 07:37:17,,1321253304,7/12/2014 07:36:58,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,INCREASED BLOOD PRESSURE,120-130-136,44,HYPERTENSION,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 07:47:54,,1321256383,7/12/2014 07:47:33,clixsense,1,27969116,NLD,04,Veendam,185.12.216.74,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,INCREASED BLOOD PRESSURE (BP),120-130-136-145,44,HYPERTENSION,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 07:58:56,,1321260137,7/12/2014 07:58:32,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,INCREASED BLOOD PRESSURE (BP),120-130-136-145,44,HYPERTENSION,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 08:00:16,,1321260586,7/12/2014 07:59:43,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,INCREASED BLOOD PRESSURE,120-130-136,44,HYPERTENSION,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 08:01:29,,1321261082,7/12/2014 08:00:55,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,well controlled hypertension is treatment of INCREASED BLOOD PRESSURE (BP),28-33-44-57-107-117-120-130-136-145,44-57-60-71-75,HYPERTENSION is alarmingly low worldwide,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 08:17:42,,1321265602,7/12/2014 08:17:40,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,to treatment of INCREASED BLOOD PRESSURE are being,104-107-117-120-130-136-150-154,23-28-33-44-57-60-71,with well controlled HYPERTENSION is alarmingly low,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 08:25:08,,1321268149,7/12/2014 08:25:03,neodev,1,11051762,NLD,09,Utrecht,87.212.164.10,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,to treatment of INCREASED BLOOD PRESSURE are being,104-107-117-120-130-136-150-154,23-28-33-44-57-60-71,with well controlled HYPERTENSION is alarmingly low,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568359,7/12/2014 08:37:39,,1321272439,7/12/2014 08:36:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,120,44,,,144,56,INCREASED BLOOD PRESSURE,HYPERTENSION,INCREASED BLOOD PRESSURE,120-130-136,44,HYPERTENSION,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought.,120 130 136,44,120,44,144,56,-1,RO-has_definitional_manifestation,904726,The number of patients with well-controlled hypertension is alarmingly low worldwide and new approaches to treatment of increased blood pressure (BP) are being sought,increased blood pressure,hypertension
502568360,7/12/2014 07:22:22,,1321248397,7/12/2014 07:21:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,"INTESTINAL METAPLASIA and gastric dysplasias and carcinomas,",146-157-168-184-192-203-207,146-157-168-184-192-203-207,"intestinal metaplasia and GASTRIC DYSPLASIAS and carcinomas,","The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 07:30:03,,1321251179,7/12/2014 07:29:49,prodege,1.0,6316959,GBR,"","",87.112.13.121,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,INTESTINAL METAPLASIA,146-157,184-192,GASTRIC DYSPLASIAS,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 07:36:57,,1321253253,7/12/2014 07:36:37,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,INTESTINAL METAPLASIA,146-157,184-192,GASTRIC DYSPLASIAS,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 07:38:42,,1321253739,7/12/2014 07:38:19,gifthulk,1,22552178,AUS,05,Adelaide,14.2.2.200,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,INTESTINAL METAPLASIA,146-157,184-192,GASTRIC DYSPLASIAS,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 07:47:03,,1321256082,7/12/2014 07:46:36,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,INTESTINAL METAPLASIA,146-157,184-192-207,"GASTRIC DYSPLASIAS carcinomas,","The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 07:49:10,,1321256748,7/12/2014 07:48:07,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,INTESTINAL METAPLASIA,146-157,184-192,GASTRIC DYSPLASIAS,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 07:57:52,,1321259747,7/12/2014 07:57:38,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,INTESTINAL METAPLASIA,146-157,184-192,GASTRIC DYSPLASIAS,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 08:14:16,,1321264719,7/12/2014 08:13:44,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,"cases of INTESTINAL METAPLASIA and of gastric dysplasias and carcinomas,",137-143-146-157-168-177-184-192-203-207,121-137-143-146-157-168-177-180-184-192-203-207,"contrast cases of intestinal metaplasia and of the GASTRIC DYSPLASIAS and carcinomas,","The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 08:19:13,,1321266094,7/12/2014 08:19:10,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,all cases of INTESTINAL METAPLASIA and some of,133-137-143-146-157-168-172-177,172-177-180-184-192-203-207-219,"some of the GASTRIC DYSPLASIAS and carcinomas, where","The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568360,7/12/2014 08:26:15,,1321268620,7/12/2014 08:26:10,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,146,184,,,167,202,INTESTINAL METAPLASIA,GASTRIC DYSPLASIAS,all cases of INTESTINAL METAPLASIA and some of,133-137-143-146-157-168-172-177,172-177-180-184-192-203-207-219,"some of the GASTRIC DYSPLASIAS and carcinomas, where","The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present.",146 157,184 192,146,184,167,202,-1,RO-disease_may_have_finding,902580,"The intestinal-type isoenzyme, however, did not occur in intact gastric mucosa or in inflammatory epithelial changes, in contrast to all cases of intestinal metaplasia and some of the gastric dysplasias and carcinomas, where it was present",intestinal metaplasia,gastric dysplasias
502568361,7/12/2014 07:23:33,,1321248838,7/12/2014 07:22:51,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,169,120,,,178,124,DYSPLASIA,HSIL,time of DYSPLASIA.,166-169-161,96-112-119-126-129-87,squamous intraepithelial lesion (HSIL) or LSIL,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 07:34:47,,1321252686,7/12/2014 07:34:02,clixsense,1,6344740,USA,WA,Longview,71.193.162.200,169,120,,,178,124,DYSPLASIA,HSIL,DYSPLASIA.,169,76-81-87-96-112-119-80,high - grade squamous intraepithelial lesion (HSIL),Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 07:42:53,,1321254871,7/12/2014 07:42:30,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,169,120,,,178,124,DYSPLASIA,HSIL,DYSPLASIA.,169,119,(HSIL),Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 07:45:30,,1321255658,7/12/2014 07:44:44,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,169,120,,,178,124,DYSPLASIA,HSIL,squamous intraepithelial lesion (HSIL) LSIL DYSPLASIA.,87-96-112-119-169-129,87-96-112-119-129,squamous intraepithelial lesion (HSIL) LSIL,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 08:01:05,,1321260943,7/12/2014 08:00:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,169,120,,,178,124,DYSPLASIA,HSIL,DYSPLASIA.,169,76-81-96-112-119-87,high grade squamous intraepithelial lesion (HSIL),Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 08:09:14,,1321263363,7/12/2014 08:08:34,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,169,120,,,178,124,DYSPLASIA,HSIL,Pap smears reliable screening of DYSPLASIA.,0-4-16-28-166-169,76-81-87-96-112-119-126-129-134-137-141,high grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 08:20:36,,1321266623,7/12/2014 08:20:33,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,169,120,,,178,124,DYSPLASIA,HSIL,the time of DYSPLASIA.,157-161-166-169,96-112-119-126-129-134,intraepithelial lesion (HSIL) or LSIL in,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 08:22:01,,1321267107,7/12/2014 08:21:37,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,169,120,,,178,124,DYSPLASIA,HSIL,squamous intraepithelial the time of DYSPLASIA.,87-157-161-166-169-96,68-96-112-119-126-129-134-169,CIN intraepithelial lesion (HSIL) or LSIL in dysplasia.,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 08:28:11,,1321269472,7/12/2014 08:26:49,neodev,1,20929875,USA,MA,Boston,71.174.188.90,169,120,,,178,124,DYSPLASIA,HSIL,DYSPLASIA.,169,76-81-87-96-112-119,high grade squamous intraepithelial lesion (HSIL),Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568361,7/12/2014 08:35:20,,1321271790,7/12/2014 08:35:05,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,169,120,,,178,124,DYSPLASIA,HSIL,DYSPLASIA.,169,76-81-96-112-119-87,high grade squamous intraepithelial lesion (HSIL),Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia.,169,,169,120,178,124,1,RO-disease_has_finding,901923,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high-grade squamous intraepithelial lesion (HSIL) or LSIL in Pap smears taken at the time of dysplasia,dysplasia,HSIL
502568362,7/12/2014 07:24:52,,1321249279,7/12/2014 07:24:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,cause of THROMBOCYTOPENIA,61-67-70,0-6-17-34,Acute IDIOPATHIC THROMBOCYTOPENIC PURPURA,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 07:28:24,,1321250676,7/12/2014 07:28:02,prodege,1.0,6316959,GBR,"","",87.112.13.121,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,THROMBOCYTOPENIA,70,6-17-34,IDIOPATHIC THROMBOCYTOPENIC PURPURA,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 07:38:28,,1321253667,7/12/2014 07:37:50,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,idiopathic thrombocytopenic purpura THROMBOCYTOPENIA,6-17-34-70,6-17-34-70,IDIOPATHIC THROMBOCYTOPENIC PURPURA thrombocytopenia,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 07:38:46,,1321253751,7/12/2014 07:38:31,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,THROMBOCYTOPENIA,70,0-6-17-34,Acute IDIOPATHIC THROMBOCYTOPENIC PURPURA,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 07:46:16,,1321255870,7/12/2014 07:45:55,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,THROMBOCYTOPENIA,70,6-17-34,IDIOPATHIC THROMBOCYTOPENIC PURPURA,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 08:14:47,,1321264824,7/12/2014 08:14:18,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,"Acute idiopathic thrombocytopenic purpura is common cause of THROMBOCYTOPENIA in childhood,",0-6-17-34-54-61-67-70-87-90-42,0-6-17-34-54-61-67-70-87-90,"Acute IDIOPATHIC THROMBOCYTOPENIC PURPURA common cause of thrombocytopenia in childhood,","Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 08:17:26,,1321265531,7/12/2014 08:17:01,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,THROMBOCYTOPENIA,70,6-17-34,IDIOPATHIC THROMBOCYTOPENIC PURPURA,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 08:35:51,,1321271932,7/12/2014 08:35:18,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,THROMBOCYTOPENIA,70,6-17-34,IDIOPATHIC THROMBOCYTOPENIC PURPURA,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 08:49:09,,1321275959,7/12/2014 08:49:03,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,"most common cause of THROMBOCYTOPENIA in childhood, and",54-61-67-70-87-90-101-49,0-6-17-34-42-45-49-54,Acute IDIOPATHIC THROMBOCYTOPENIC PURPURA is the most common,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568362,7/12/2014 08:52:26,,1321277034,7/12/2014 08:52:07,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,70,6,,,86,41,THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,Acute idiopathic thrombocytopenic purpura THROMBOCYTOPENIA,0-6-17-34-70,0-6-17-34-70,Acute IDIOPATHIC THROMBOCYTOPENIC PURPURA thrombocytopenia,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia.",70,6 17 34,70,6,86,41,-1,RO-has_definitional_manifestation,904858,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of idiopathic thrombocytopenic purpura is made clinically based on the exclusion of other causes of thrombocytopenia",thrombocytopenia,idiopathic thrombocytopenic purpura
502568363,7/12/2014 07:35:29,,1321252891,7/12/2014 07:35:10,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,CADMIUM,104,159-167,CADMIUM TOXICITY,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 07:59:17,,1321260279,7/12/2014 07:58:57,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,CADMIUM ion,104-112,159-167,CADMIUM TOXICITY,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 08:25:20,,1321268248,7/12/2014 08:25:16,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,protection against the CADMIUM ion in the,81-92-100-104-112-116-119,137-145-149-159-167-176-181-184,"milieu, but promoting CADMIUM TOXICITY when it is","The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 08:48:07,,1321275627,7/12/2014 08:47:40,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,CADMIUM cadmium toxicity,104-159-167,159-167,CADMIUM TOXICITY,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 08:56:40,,1321278379,7/12/2014 08:56:25,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,CADMIUM,104,159-167,CADMIUM TOXICITY,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 09:02:36,,1321280495,7/12/2014 09:02:15,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,"CADMIUM ion in the intracellular milieu,",104-112-116-119-123-137,159-167,CADMIUM TOXICITY,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 09:03:26,,1321280799,7/12/2014 09:03:10,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,CADMIUM ion,104-112,159-167,CADMIUM TOXICITY,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 09:03:41,,1321280904,7/12/2014 09:03:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,CADMIUM ion,104-112,159-167,CADMIUM TOXICITY,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 09:09:58,,1321282966,7/12/2014 09:06:41,neodev,1.0,20929875,USA,MA,Boston,71.174.188.90,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,protection against the CADMIUM ion in the,81-92-100-104-112-116-119,137-145-149-159-167-176-181-184,"milieu, but promoting CADMIUM TOXICITY when it is","The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568363,7/12/2014 09:11:40,,1321283502,7/12/2014 09:11:33,neodev,1,11580174,CAN,QC,Montréal,208.67.168.71,104,159,,,111,175,CADMIUM,CADMIUM TOXICITY,protection against the CADMIUM ion in the,81-92-100-104-112-116-119,137-145-149-159-167-176-181-184,"milieu, but promoting CADMIUM TOXICITY when it is","The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine.",104,159 167,104,159,111,175,-1,RO-has_causative_agent,903970,"The results suggest that cadmium-thionein may play a paradoxical role, providing protection against the cadmium ion in the intracellular milieu, but promoting cadmium toxicity when it is present in sufficient amounts in the lumen of the intestine",cadmium,cadmium toxicity
502568364,7/12/2014 07:35:12,,1321252793,7/12/2014 07:34:35,prodege,1.0,6316959,GBR,"","",87.112.13.121,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,estrogen secreting MALIGNANT SEX CORD STROMAL TUMOR,136-146-156-160-165-173-127,49-58-72-81-93-106-40,complete androgen insensitivity syndrome (TESTICULAR FEMINIZATION SYNDROME),We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 07:36:39,,1321253169,7/12/2014 07:35:56,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,estrogen secreting MALIGNANT SEX CORD STROMAL TUMOR,127-136-146-156-160-165-173,49-58-72-81-93-106-40,complete androgen insensitivity syndrome (TESTICULAR FEMINIZATION SYNDROME),We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 07:43:24,,1321255050,7/12/2014 07:42:46,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,estrogen secreting MALIGNANT SEX CORD STROMAL TUMOR intraabdominal testis.,127-136-146-156-160-165-173-195-210,72-81-93-106,syndrome (TESTICULAR FEMINIZATION SYNDROME),We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 08:19:10,,1321266082,7/12/2014 08:18:56,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,an estrogen secreting MALIGNANT SEX CORD STROMAL TUMOR developed in an,124-127-136-146-156-160-165-173-179-189-192,58-72-81-93-106-116-119-124,insensitivity syndrome (TESTICULAR FEMINIZATION SYNDROME) in whom an,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 08:26:20,,1321268692,7/12/2014 08:26:16,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,an estrogen secreting MALIGNANT SEX CORD STROMAL TUMOR developed in an,124-127-136-146-156-160-165-173-179-189-192,58-72-81-93-106-116-119-124,insensitivity syndrome (TESTICULAR FEMINIZATION SYNDROME) in whom an,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 08:36:30,,1321272130,7/12/2014 08:36:07,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,estrogen secreting MALIGNANT SEX CORD STROMAL TUMOR,127-136-146-156-160-165-173,81-93-106,(TESTICULAR FEMINIZATION SYNDROME),We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 08:38:56,,1321272832,7/12/2014 08:38:39,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,MALIGNANT SEX CORD STROMAL TUMOR,146-156-160-165-173,93-106,FEMINIZATION SYNDROME),We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 08:50:10,,1321276306,7/12/2014 08:49:48,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,androgen insensitivity syndrome MALIGNANT SEX CORD STROMAL TUMOR,49-58-72-146-156-160-165-173,49-58-72-93-106,androgen insensitivity syndrome FEMINIZATION SYNDROME),We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 08:54:42,,1321277713,7/12/2014 08:54:16,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,an estrogen secreting MALIGNANT SEX CORD STROMAL TUMOR,124-127-136-146-156-160-165-173,49-58-72-81-93-106,androgen insensitivity syndrome (TESTICULAR FEMINIZATION SYNDROME),We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568364,7/12/2014 08:56:46,,1321278467,7/12/2014 08:55:21,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,146,82,,,178,114,MALIGNANT SEX CORD STROMAL TUMOR,TESTICULAR FEMINIZATION SYNDROME,estrogen secreting MALIGNANT SEX CORD STROMAL TUMOR,127-136-146-156-160-165-173,81-93-106,(TESTICULAR FEMINIZATION SYNDROME),We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis.,146 156 160 165 173,93 106,146,82,178,114,-1,RO-has_manifestation,906067,We report on a 68-year-old patient with complete androgen insensitivity syndrome (testicular feminization syndrome) in whom an estrogen-secreting malignant sex cord stromal tumor developed in an intraabdominal testis,malignant sex cord stromal tumor,testicular feminization syndrome
502568365,7/12/2014 07:25:18,,1321249482,7/12/2014 07:24:52,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,widespread PAIN and diffuse tenderness,52-63-68-72-80,4-17-32-35-26,FIBROMYALGIA SYNDROME (FMS) is characterized,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 07:42:21,,1321254666,7/12/2014 07:41:55,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,PAIN,63,4-17,FIBROMYALGIA SYNDROME,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 07:44:43,,1321255408,7/12/2014 07:44:19,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,PAIN,63,4-17,FIBROMYALGIA SYNDROME,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 07:54:27,,1321258596,7/12/2014 07:54:15,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,PAIN,63,4-17-26,FIBROMYALGIA SYNDROME (FMS),The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 08:04:32,,1321261962,7/12/2014 08:04:07,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,PAIN,63,4-17,FIBROMYALGIA SYNDROME,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 08:15:02,,1321264871,7/12/2014 08:14:50,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,PAIN,63,4-17,FIBROMYALGIA SYNDROME,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 08:19:08,,1321266079,7/12/2014 08:18:09,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,Fibromyalgia syndrome PAIN,4-63-17,4-17,FIBROMYALGIA SYNDROME,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 08:22:58,,1321267443,7/12/2014 08:22:50,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,characterized by widespread PAIN and diffuse tenderness,35-49-52-63-68-72-80,0-4-17-32-35,The FIBROMYALGIA SYNDROME is characterized,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 08:29:45,,1321270002,7/12/2014 08:29:24,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,PAIN,63,4-17,FIBROMYALGIA SYNDROME,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568365,7/12/2014 08:49:03,,1321275916,7/12/2014 08:46:09,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,63,4,,,67,25,PAIN,FIBROMYALGIA SYNDROME,widespread PAIN and diffuse tenderness,52-63-68-72-80,4-17,FIBROMYALGIA SYNDROME,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations.,63,4 17,63,4,67,25,1,RO-has_definitional_manifestation,904620,The Fibromyalgia syndrome (FMS) is characterized by widespread pain and diffuse tenderness in specified locations,pain,Fibromyalgia syndrome
502568366,7/12/2014 07:37:00,,1321253256,7/12/2014 07:36:49,prodege,1.0,6316959,GBR,"","",87.112.13.121,75,128,,,82,136,SEIZURE,EPILEPSY,SEIZURE,75,128,EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 07:38:59,,1321253818,7/12/2014 07:38:44,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,75,128,,,82,136,SEIZURE,EPILEPSY,SEIZURE,75,128,EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 07:43:34,,1321255066,7/12/2014 07:43:15,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,75,128,,,82,136,SEIZURE,EPILEPSY,SEIZURE,75,128,EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 07:51:10,,1321257476,7/12/2014 07:50:51,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,75,128,,,82,136,SEIZURE,EPILEPSY,to lead to SEIZURE epilepsy.,64-67-72-75-128,109-119-122-128,difficult to treat EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 07:51:26,,1321257562,7/12/2014 07:50:32,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,75,128,,,82,136,SEIZURE,EPILEPSY,SEIZURE,75,128,EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 07:55:42,,1321259048,7/12/2014 07:55:08,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,75,128,,,82,136,SEIZURE,EPILEPSY,SEIZURE,75,128,EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 08:01:51,,1321261165,7/12/2014 08:01:37,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,75,128,,,82,136,SEIZURE,EPILEPSY,SEIZURE freedom,75-83,119-122-128-109,difficult to treat EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 08:12:31,,1321264283,7/12/2014 08:12:16,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,75,128,,,82,136,SEIZURE,EPILEPSY,SEIZURE freedom,75-83,128,EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 08:17:37,,1321265590,7/12/2014 08:17:34,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,75,128,,,82,136,SEIZURE,EPILEPSY,to lead to SEIZURE freedom for patients,64-67-72-75-83-91-95,109-119-122-128,difficult to treat EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568366,7/12/2014 08:26:44,,1321268845,7/12/2014 08:26:39,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,75,128,,,82,136,SEIZURE,EPILEPSY,to lead to SEIZURE freedom for patients,64-67-72-75-83-91-95,109-119-122-128,difficult to treat EPILEPSY.,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy.,75,128,75,128,82,136,-1,RO-has_definitional_manifestation,904836,Serial addition to 3 or more antiepileptic drugs is less likely to lead to seizure freedom for patients with difficult-to-treat epilepsy,seizure,epilepsy
502568367,7/12/2014 07:22:50,,1321248590,7/12/2014 07:22:23,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,developed GRAVES' DISEASE,45-55-63,106-115-124-127,clinical features of THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 07:31:23,,1321251640,7/12/2014 07:31:06,prodege,1.0,6316959,GBR,"","",87.112.13.121,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,55-63,127,THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 07:32:40,,1321252035,7/12/2014 07:32:18,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,55-63,127,THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 07:34:48,,1321252709,7/12/2014 07:34:28,elite,1.0,28322695,GBR,G8,Dewsbury,217.44.206.25,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,55-63,127,THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 07:35:53,,1321252970,7/12/2014 07:35:30,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,55-63,127,THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 07:35:58,,1321252990,7/12/2014 07:35:15,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE thyrotoxicosis,55-63-127,55-63-127,Graves' disease THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 07:48:24,,1321256558,7/12/2014 07:48:09,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,fully developed GRAVES' DISEASE,39-55-63-45,127,THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 07:56:04,,1321259166,7/12/2014 07:55:43,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,55-63,127,THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 08:12:59,,1321264363,7/12/2014 08:12:46,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE are,55-63-71,127,THYROTOXICOSIS,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568367,7/12/2014 08:47:07,,1321275174,7/12/2014 08:47:03,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,55,127,,,70,141,GRAVES' DISEASE,THYROTOXICOSIS,"with fully developed GRAVES' DISEASE are difficult to overlook,",34-39-45-55-63-71-75-85-88,106-115-124-127-142-147-152-102,the clinical features of THYROTOXICOSIS vary with the,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",55 63,127,55,127,70,141,-1,RO-cause_of,900400,"The classic features of a patient with fully developed Graves' disease are difficult to overlook, but the clinical features of thyrotoxicosis vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues",Graves' disease,thyrotoxicosis
502568368,7/12/2014 07:10:42,,1321244586,7/12/2014 07:10:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,15,90,,,19,104,BONE,PSEUDARTHROSIS,Instability of BONE fragments,0-12-15-20,74-87-90,pathogenesis of PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 07:31:05,,1321251525,7/12/2014 07:30:48,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,15,90,,,19,104,BONE,PSEUDARTHROSIS,BONE,15,90,PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 07:36:47,,1321253205,7/12/2014 07:36:36,prodege,1.0,6316959,GBR,"","",87.112.13.121,15,90,,,19,104,BONE,PSEUDARTHROSIS,BONE fragments,15-20,90,PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 07:36:57,,1321253255,7/12/2014 07:36:41,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,15,90,,,19,104,BONE,PSEUDARTHROSIS,BONE,15,90,PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 07:51:23,,1321257540,7/12/2014 07:50:44,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,15,90,,,19,104,BONE,PSEUDARTHROSIS,Instability of BONE fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,0-12-15-20-30-33-42-45-49-54-64-74-87-90-71,0-12-20-30-33-42-45-49-54-64-71-74-87-90-15,Instability of bone fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 07:56:23,,1321259318,7/12/2014 07:56:05,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,15,90,,,19,104,BONE,PSEUDARTHROSIS,BONE,15,90,PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 08:21:05,,1321266783,7/12/2014 08:20:46,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,15,90,,,19,104,BONE,PSEUDARTHROSIS,BONE pseudarthrosis.,15-90,90,PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 08:26:09,,1321268568,7/12/2014 08:25:52,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,15,90,,,19,104,BONE,PSEUDARTHROSIS,Instability of BONE fragments is regarded,0-12-15-20-30-33,71-74-87-90,in pathogenesis of PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 08:29:23,,1321269909,7/12/2014 08:29:02,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,15,90,,,19,104,BONE,PSEUDARTHROSIS,BONE,15,90,PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568368,7/12/2014 08:32:29,,1321270945,7/12/2014 08:32:19,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,15,90,,,19,104,BONE,PSEUDARTHROSIS,BONE fragments,15-20,90,PSEUDARTHROSIS.,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis.,15,90,15,90,19,104,1,RO-has_finding_site,905494,Instability of bone fragments is regarded as the most important factor in pathogenesis of pseudarthrosis,bone,pseudarthrosis
502568369,7/12/2014 07:27:22,,1321250298,7/12/2014 07:26:43,prodege,1.0,6316959,GBR,"","",87.112.13.121,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,ESOPHAGUS,122,32-43,ESOPHAGEAL CANCER,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 07:35:13,,1321252809,7/12/2014 07:34:24,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,esophageal cancer pulmonary bullae ESOPHAGUS,32-43-67-122-77,32-43-67-77,ESOPHAGEAL CANCER pulmonary bullae,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 07:40:43,,1321254285,7/12/2014 07:39:34,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,ESOPHAGUS,122,32-43,ESOPHAGEAL CANCER,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 07:45:29,,1321255651,7/12/2014 07:45:04,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,ESOPHAGUS,122,32-43,ESOPHAGEAL CANCER,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 08:12:18,,1321264234,7/12/2014 08:11:37,prodege,1,21891314,AUS,07,Glen Iris,58.6.248.249,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,ESOPHAGUS and,122-132,32-43,ESOPHAGEAL CANCER,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 08:36:45,,1321272197,7/12/2014 08:36:32,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,ESOPHAGUS,122,32-43,ESOPHAGEAL CANCER,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 08:51:29,,1321276714,7/12/2014 08:51:13,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,esophageal cancer ESOPHAGUS,32-43-122,32-43,ESOPHAGEAL CANCER,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 08:51:41,,1321276792,7/12/2014 08:50:40,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,operation on the ESOPHAGUS and lung,105-115-118-122-132-136,32-43-50-62-67-77,ESOPHAGEAL CANCER complicated with pulmonary bullae,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 08:58:19,,1321278916,7/12/2014 08:57:53,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,ESOPHAGUS,122,32-43,ESOPHAGEAL CANCER,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568369,7/12/2014 08:58:22,,1321278942,7/12/2014 08:58:05,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,122,32,,,131,49,ESOPHAGUS,ESOPHAGEAL CANCER,ESOPHAGUS,122,32-43,ESOPHAGEAL CANCER,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation.",122,32 43,122,32,131,49,1,RO-disease_has_primary_anatomic_site,902460,"Since 1982, three patients with esophageal cancer complicated with pulmonary bullae have been treated by operation on the esophagus and lung in one performance: In all the patients, the bullae were on the same side of the operation",esophagus,esophageal cancer
502568370,7/12/2014 07:31:39,,1321251687,7/12/2014 07:30:16,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS Erythematosus,33-42-48,113-122-128,SYSTEMIC LUPUS ERYTHEMATOSUS,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 07:34:01,,1321252464,7/12/2014 07:33:24,prodege,1.0,6316959,GBR,"","",87.112.13.121,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS Erythematosus,33-42-48,113-122-128,SYSTEMIC LUPUS ERYTHEMATOSUS,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 07:35:31,,1321252900,7/12/2014 07:35:00,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS Erythematosus Normal;,33-42-48-63,113-122-128,SYSTEMIC LUPUS ERYTHEMATOSUS,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 07:51:56,,1321257685,7/12/2014 07:51:27,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS Erythematosus,33-42-48,113-122-128,SYSTEMIC LUPUS ERYTHEMATOSUS,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 07:53:35,,1321258291,7/12/2014 07:52:10,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,42,113-122-128,SYSTEMIC LUPUS ERYTHEMATOSUS,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 08:16:16,,1321265223,7/12/2014 08:16:00,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Studies for Systemic LUPUS Erythematosus Normal; Laboratory,21-29-33-42-48-63-80,101-109-113-122-128-142-148-154-163-169,Studies for SYSTEMIC LUPUS ERYTHEMATOSUS Test Notes Complete blood count,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 08:40:52,,1321273420,7/12/2014 08:40:25,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,42,113-122-128,SYSTEMIC LUPUS ERYTHEMATOSUS,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 08:47:32,,1321275389,7/12/2014 08:47:27,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Studies for Systemic LUPUS Erythematosus Normal; Laboratory and,21-29-33-42-48-63-80-91,95-101-109-113-122-128-142-148-154-91,and Other Studies for SYSTEMIC LUPUS ERYTHEMATOSUS Test Notes Complete,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 08:52:48,,1321277103,7/12/2014 08:52:27,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS Erythematosus,33-42-48,113-122-128,SYSTEMIC LUPUS ERYTHEMATOSUS,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568370,7/12/2014 08:58:57,,1321279166,7/12/2014 08:58:23,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,42,113,,,47,141,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS Erythematosus Normal;,33-42-48-63,113-122-128,SYSTEMIC LUPUS ERYTHEMATOSUS,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease.,42,113 122 128,42,113,47,141,-1,RO-has_manifestation,906076,Laboratory and Other Studies for Systemic Lupus Erythematosus  Normal;          Laboratory and Other Studies for Systemic Lupus Erythematosus Test  Notes Complete blood count  The most common anemia in SLE is from chronic disease,Lupus,Systemic Lupus Erythematosus
502568371,7/12/2014 07:25:39,,1321249621,7/12/2014 07:25:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,The presence of MICROVASCULAR PROLIFERATION,0-4-13-16-30,57-70-80-83-96,histological diagnosis of GLIOBLASTOMA multiforme.,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 07:30:46,,1321251426,7/12/2014 07:30:25,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,MICROVASCULAR PROLIFERATION,16-30,83,GLIOBLASTOMA,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 07:37:15,,1321253293,7/12/2014 07:36:37,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,MICROVASCULAR PROLIFERATION glioblastoma multiforme.,16-30-83-96,16-30-83-96,microvascular proliferation GLIOBLASTOMA multiforme.,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 07:46:32,,1321255956,7/12/2014 07:46:15,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,MICROVASCULAR PROLIFERATION,16-30,83-96,GLIOBLASTOMA multiforme.,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 07:46:35,,1321255957,7/12/2014 07:46:13,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,MICROVASCULAR PROLIFERATION,16-30,83,GLIOBLASTOMA,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 08:02:48,,1321261461,7/12/2014 08:02:32,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,MICROVASCULAR PROLIFERATION,16-30,83-96,GLIOBLASTOMA multiforme.,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 08:15:50,,1321265083,7/12/2014 08:15:38,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,MICROVASCULAR PROLIFERATION,16-30,83-96,GLIOBLASTOMA multiforme.,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 08:16:37,,1321265310,7/12/2014 08:16:17,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,presence of MICROVASCULAR PROLIFERATION leads to diagnosis of glioblastoma multiforme.,4-13-16-30-44-50-70-80-83-96,16-30-44-57-70-80-83-96-50,microvascular proliferation leads to histological diagnosis of GLIOBLASTOMA multiforme.,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 08:17:31,,1321265558,7/12/2014 08:17:28,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,The presence of MICROVASCULAR PROLIFERATION leads to the,0-4-13-16-30-44-50-53,57-70-80-83-96,histological diagnosis of GLIOBLASTOMA multiforme.,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568371,7/12/2014 08:30:39,,1321270333,7/12/2014 08:30:21,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,16,83,,,43,95,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA,MICROVASCULAR PROLIFERATION,16-30,83-96,GLIOBLASTOMA multiforme.,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme.,16 30,83,16,83,43,95,1,RO-disease_has_finding,901588,The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme,microvascular proliferation,glioblastoma
502568372,7/12/2014 07:34:25,,1321252590,7/12/2014 07:34:03,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,28,88,,,33,94,ML II,ML III,ML II,28-31,88-91,ML III,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 07:37:28,,1321253345,7/12/2014 07:37:02,prodege,1.0,6316959,GBR,"","",87.112.13.121,28,88,,,33,94,ML II,ML III,ML II and III,28-31-34-38,88-91,ML III,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 07:40:10,,1321254083,7/12/2014 07:39:56,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,28,88,,,33,94,ML II,ML III,ML II,28-31,88-91,ML III,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 07:45:54,,1321255769,7/12/2014 07:45:30,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,28,88,,,33,94,ML II,ML III,ML II,28-31,88-91,ML III,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 07:48:45,,1321256645,7/12/2014 07:48:24,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,28,88,,,33,94,ML II,ML III,ML II,28-31,88-91,ML III,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 07:53:08,,1321258124,7/12/2014 07:52:48,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,28,88,,,33,94,ML II,ML III,in ML II,25-28-31,88-91,ML III,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 07:55:07,,1321258890,7/12/2014 07:54:29,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,28,88,,,33,94,ML II,ML III,ML II and III,28-31-34-38,88-91,ML III,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 08:18:55,,1321266004,7/12/2014 08:18:54,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,28,88,,,33,94,ML II,ML III,GNPTAB result in ML II and III whereas,11-18-25-28-31-34-38-42,74-79-85-88-91-95,only found in ML III patients.,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 08:36:15,,1321272048,7/12/2014 08:35:53,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,28,88,,,33,94,ML II,ML III,ML II,28-31,88-91,ML III,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568372,7/12/2014 08:47:26,,1321275334,7/12/2014 08:47:21,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,28,88,,,33,94,ML II,ML III,GNPTAB result in ML II and III,11-18-25-28-31-34-38,79-85-88-91-95,found in ML III patients.,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients.,28 31,88 91,28,88,33,94,-1,RO-has_manifestation,906209,Defects in GNPTAB result in ML II and III whereas mutations in GNPTG were only found in ML III patients,ML II,ML III
502568373,7/12/2014 07:39:06,,1321253845,7/12/2014 07:38:47,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS,110-116-126,147,WART,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 07:44:42,,1321255381,7/12/2014 07:44:04,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS (HPV) keratinocyte proliferation,110-116-126-132-191-204,110-116-126-132-147,human papilloma virus (HPV) WART,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 07:58:18,,1321259879,7/12/2014 07:57:44,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS (HPV),110-116-126-132,147-152-163-170-174-188-191-204,WART regression and the normalisation of keratinocyte proliferation,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 08:03:07,,1321261566,7/12/2014 08:02:50,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS (HPV),110-116-126-132,147,WART,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 08:33:23,,1321271196,7/12/2014 08:33:10,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS,110-116-126,147,WART,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 08:47:02,,1321275167,7/12/2014 08:46:51,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,to a reduction in HUMAN PAPILLOMA VIRUS load; to,95-97-107-110-116-126-138-144-92,132-138-144-147-152-163-167-126,virus (HPV) load; to WART regression and to,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 08:50:39,,1321276452,7/12/2014 08:49:04,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS (HPV),110-116-126-132,147-152-163-174-188-191-204,WART regression and normalisation of keratinocyte proliferation,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 08:52:05,,1321276931,7/12/2014 08:51:47,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS,110-116-126,110-116-126-132-147,human papilloma virus (HPV) WART,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 08:55:51,,1321278124,7/12/2014 08:55:24,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS,110-116-126,147,WART,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568373,7/12/2014 09:00:10,,1321279533,7/12/2014 08:59:46,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,110,147,,,131,151,HUMAN PAPILLOMA VIRUS,WART,HUMAN PAPILLOMA VIRUS,110-116-126,147-152,WART regression,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,110 116 126,147,110,147,131,151,-1,RO-has_causative_agent,903914,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in human papilloma virus (HPV) load; to wart regression and to the normalisation of keratinocyte proliferation without evidence of scarring,human papilloma virus,wart
502568374,7/12/2014 07:28:17,,1321250630,7/12/2014 07:27:44,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,HEPATITIS A VIRUS,52-62-64,22,HEPATITIS,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 07:55:43,,1321259054,7/12/2014 07:55:05,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,exposure to HEPATITIS A VIRUS in international travelers.,40-49-52-62-64-74-77-91,22-34-40-52-62-64-74-77-91,HEPATITIS after exposure hepatitis A virus in international travelers.,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 08:01:36,,1321261104,7/12/2014 08:01:23,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,HEPATITIS A VIRUS,52-62-64,22-32,HEPATITIS A,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 08:15:37,,1321265008,7/12/2014 08:15:23,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,HEPATITIS A VIRUS,52-62-64,22-32,HEPATITIS A,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 08:20:22,,1321266532,7/12/2014 08:20:20,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,after exposure to HEPATITIS A VIRUS and in international,34-40-49-52-62-64-70-74-77,0-8-19-22-32-34-40,Update: Prevention of HEPATITIS A after exposure,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 08:32:23,,1321270887,7/12/2014 08:31:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,HEPATITIS A VIRUS,52-62-64,22,HEPATITIS,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 08:48:35,,1321275769,7/12/2014 08:48:30,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,after exposure to HEPATITIS A VIRUS and in international travelers.,34-40-49-52-62-64-70-74-77-91,0-8-19-22-32-34-40-52,Update: Prevention of HEPATITIS A after exposure hepatitis,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 08:59:52,,1321279459,7/12/2014 08:59:38,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,HEPATITIS A VIRUS,52-62-64,22-32,HEPATITIS A,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 09:00:35,,1321279653,7/12/2014 09:00:11,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,HEPATITIS A VIRUS,52-62-64,22-32,HEPATITIS A,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568374,7/12/2014 09:03:29,,1321280809,7/12/2014 09:03:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,52,22,,,69,31,HEPATITIS A VIRUS,HEPATITIS,HEPATITIS A VIRUS,52-62-64,22-32,HEPATITIS A,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers.,52 62 64,22,52,22,69,31,-1,RO-has_causative_agent,903786,Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers,hepatitis A virus,hepatitis
502568375,7/12/2014 07:29:07,,1321250907,7/12/2014 07:28:45,prodege,1.0,6316959,GBR,"","",87.112.13.121,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI.,197-206,183-188,"LYME DISEASE,","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 07:31:47,,1321251716,7/12/2014 07:31:30,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI.,197-206,183-188,"LYME DISEASE,","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 07:39:55,,1321254029,7/12/2014 07:39:38,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI.,197-206,183-188,"LYME DISEASE,","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 07:44:28,,1321255324,7/12/2014 07:44:08,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI.,197-206,183-188,"LYME DISEASE,","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 07:50:27,,1321257200,7/12/2014 07:50:12,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,"Lyme disease, BORRELIA BURGDORFERI.",183-188-197-206,164-174-180-183-188-197-206,"causative agent of LYME DISEASE, Borrelia burgdorferi.","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 07:54:28,,1321258604,7/12/2014 07:54:09,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI.,197-206,183-188,"LYME DISEASE,","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 07:54:28,,1321258632,7/12/2014 07:53:20,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, BORRELIA BURGDORFERI.",0-3-7-13-19-30-34-42-47-51-58-64-76-88-92-96-102-107-111-116-122-129-138-142-150-157-164-174-180-183-188-197-206-160,0-3-7-13-19-30-34-42-47-51-58-64-76-88-92-96-102-107-111-116-122-129-138-142-150-157-164-174-180-183-188-197-206-160,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE, Borrelia burgdorferi.","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 08:00:32,,1321260753,7/12/2014 08:00:17,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI.,197-206,183-188,"LYME DISEASE,","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 08:19:18,,1321266144,7/12/2014 08:19:16,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,"of Lyme disease, BORRELIA BURGDORFERI.",180-183-188-197-206,164-174-180-183-188-197-206,"causative agent of LYME DISEASE, Borrelia burgdorferi.","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568375,7/12/2014 08:19:44,,1321266317,7/12/2014 08:19:32,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,197,183,,,217,195,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI.,197-206,183-188,"LYME DISEASE,","Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi.",197 206,183 188,197,183,217,195,1,RO-has_causative_agent,903523,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of Lyme disease, Borrelia burgdorferi",Borrelia burgdorferi,Lyme disease
502568376,7/12/2014 07:17:29,,1321246687,7/12/2014 07:16:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,radiographically for DENTAL CARIES,160-177-181-188,65-69-76-85,the SODIUM FLUORIDE dentifrice,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 07:35:57,,1321252986,7/12/2014 07:35:32,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,DENTAL CARIES,181-188,69-76,SODIUM FLUORIDE,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 07:35:56,,1321252995,7/12/2014 07:35:32,prodege,1.0,6316959,GBR,"","",87.112.13.121,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,DENTAL CARIES,181-188,69-76-85,SODIUM FLUORIDE dentifrice,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 07:42:33,,1321254732,7/12/2014 07:42:14,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,DENTAL CARIES,181-188,69-76,SODIUM FLUORIDE,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 07:54:57,,1321258837,7/12/2014 07:54:39,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,DENTAL CARIES,181-188,69-76,SODIUM FLUORIDE,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 08:12:15,,1321264206,7/12/2014 08:11:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,and DENTAL CARIES,156-181-188,69-76-85,SODIUM FLUORIDE dentifrice,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 08:15:59,,1321265106,7/12/2014 08:15:21,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,stannous fluoride dentifrice examined clinically and radiographically for DENTAL CARIES,103-112-121-136-145-156-160-177-181-188,69-76-85-136-145-215-220-229-235-244-255,"SODIUM FLUORIDE dentifrice examined clinically one, two, three years dentifrice usage.","A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 08:20:15,,1321266491,7/12/2014 08:20:12,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,and radiographically for DENTAL CARIES initially and after,156-160-177-181-188-195-205-209,55-58-65-69-76-85-96-99,to either the SODIUM FLUORIDE dentifrice or the,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 08:25:01,,1321268068,7/12/2014 08:24:56,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,and radiographically for DENTAL CARIES initially and after,156-160-177-181-188-195-205-209,55-58-65-69-76-85-96-99,to either the SODIUM FLUORIDE dentifrice or the,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568376,7/12/2014 08:33:59,,1321271385,7/12/2014 08:33:48,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,181,69,,,194,84,DENTAL CARIES,SODIUM FLUORIDE,DENTAL CARIES,181-188,69-76,SODIUM FLUORIDE,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage.",181 188,69 76,181,69,194,84,1,RO-may_prevent,907106,"A sample of 1,824 schoolchildren was randomly assigned to either the sodium fluoride dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for dental caries initially and after one, two, and three years of dentifrice usage",dental caries,sodium fluoride
502568377,7/12/2014 07:33:28,,1321252296,7/12/2014 07:32:19,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"Haemophilus influenzae type b, 7",168-179-184-187-156,201-216,"STAPHYLOCOCCUS AUREUS,","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 07:42:44,,1321254812,7/12/2014 07:42:04,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"influenzae type b, 7 Staphylococcus aureus,",168-179-184-187-201-216,168-179-201-216-184,"influenzae type b, STAPHYLOCOCCUS AUREUS,","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 07:57:37,,1321259678,7/12/2014 07:57:05,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"7 of 22 (32%) Staphylococcus aureus,",187-189-192-195-201-216,201-216,"STAPHYLOCOCCUS AUREUS,","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 08:08:29,,1321263146,7/12/2014 08:06:07,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,7,187,201-216,"STAPHYLOCOCCUS AUREUS,","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 08:17:52,,1321265659,7/12/2014 08:17:27,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"Haemophilus influenzae type b, 7",168-179-184-187-156,187-201-216,"7 STAPHYLOCOCCUS AUREUS,","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 08:20:29,,1321266596,7/12/2014 08:20:26,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"influenzae type b, 7 of 22",168-179-184-187-189-192,189-192-195-201-216-224-227-230,"of 22 (32%) STAPHYLOCOCCUS AUREUS, 19 of 20","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 08:26:57,,1321268903,7/12/2014 08:26:51,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"influenzae type b, 7 of 22",168-179-184-187-189-192,189-192-195-201-216-224-227-230,"of 22 (32%) STAPHYLOCOCCUS AUREUS, 19 of 20","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 08:34:06,,1321271457,7/12/2014 08:32:21,neodev,1.0,20929875,USA,MA,Boston,71.174.188.90,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"influenzae type b, 7",168-179-184-187,201-216,"STAPHYLOCOCCUS AUREUS,","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 08:36:05,,1321272008,7/12/2014 08:35:39,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"Haemophilus influenzae type b, 7",168-179-184-187-156,201-216,"STAPHYLOCOCCUS AUREUS,","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568377,7/12/2014 08:48:06,,1321275615,7/12/2014 08:48:01,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,187,201,,,188,222,7,STAPHYLOCOCCUS AUREUS,"influenzae type b, 7 of 22 (32%)",168-179-184-187-189-192-195,189-192-195-201-216-224-227-230-233,"of 22 (32%) STAPHYLOCOCCUS AUREUS, 19 of 20 (95%)","Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae.",187,201 216,187,201,188,222,-1,RO-has_causative_agent,903951,"Early replicator subculturing of blood specimens after 4 to 16 h of incubation detected 135 of 217 (59%) of all positive cultures, including 56 of 64 (87%) Haemophilus influenzae type b, 7 of 22 (32%) Staphylococcus aureus, 19 of 20 (95%) pathogenic streptococci, and 20 of 24 (83%) Enterobacteriaceae",7,Staphylococcus aureus
502568378,7/12/2014 07:26:55,,1321250135,7/12/2014 07:26:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,"DYSPLASIA or carcinoma in situ,",156-166-169-179-182,111-120-130-133,CERVICAL CARCINOMA IN SITU,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 07:28:44,,1321250782,7/12/2014 07:28:25,prodege,1.0,6316959,GBR,"","",87.112.13.121,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,DYSPLASIA,156,111-120-130-133,CERVICAL CARCINOMA IN SITU,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 07:49:14,,1321256776,7/12/2014 07:48:47,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,DYSPLASIA,156,111-120-130-133,CERVICAL CARCINOMA IN SITU,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 08:00:02,,1321260547,7/12/2014 07:59:01,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,"DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women,",156-166-169-179-182-188-196-200-208-215-226-229-237,111-120-130-133-142-145-151-156-166-169,CERVICAL CARCINOMA IN SITU in women with dysplasia or carcinoma,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 08:00:41,,1321260788,7/12/2014 08:00:03,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,DYSPLASIA,156,111-120-130-133,CERVICAL CARCINOMA IN SITU,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 08:14:24,,1321264732,7/12/2014 08:14:01,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,DYSPLASIA or carcinoma,156-169-166,111-120-130-133,CERVICAL CARCINOMA IN SITU,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 08:24:15,,1321267834,7/12/2014 08:24:03,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,in women with DYSPLASIA or carcinoma in,142-145-151-156-166-169-179,94-97-106-111-120-130-133-138-142-145,or younger) with CERVICAL CARCINOMA IN SITU and in women,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 08:38:10,,1321272591,7/12/2014 08:37:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,DYSPLASIA,156,111-120-130-133,CERVICAL CARCINOMA IN SITU,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 08:46:41,,1321275039,7/12/2014 08:46:34,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,"in women with DYSPLASIA or carcinoma in situ,",142-145-151-156-166-169-179-182,94-97-106-111-120-130-133-138-142-145-9,frequency or younger) with CERVICAL CARCINOMA IN SITU and in women,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568378,7/12/2014 08:49:02,,1321275908,7/12/2014 08:48:34,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,156,111,,,165,137,DYSPLASIA,CERVICAL CARCINOMA IN SITU,herpes simplex cervical carcinoma DYSPLASIA carcinoma,22-29-111-120-156-169,22-29-111-120-130-133-156-169,herpes simplex CERVICAL CARCINOMA IN SITU dysplasia carcinoma,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",156,111 120 130 133,156,111,165,137,-1,RO-disease_has_finding,901581,"The high frequency of herpes simplex virus type 2 (HSV-2) antibodies in young women (21 years or younger) with cervical carcinoma in situ and in women with dysplasia or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation",dysplasia,cervical carcinoma in situ
502568379,7/12/2014 07:10:17,,1321244415,7/12/2014 07:09:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION.,158,49-62-72,pathogenetic view GLIOBLASTOMA,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 07:34:01,,1321252465,7/12/2014 07:33:43,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION.,158,72,GLIOBLASTOMA,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 07:35:31,,1321252895,7/12/2014 07:35:13,prodege,1.0,6316959,GBR,"","",87.112.13.121,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION.,158,72,GLIOBLASTOMA,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 07:46:14,,1321255864,7/12/2014 07:45:21,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION.,158,72,GLIOBLASTOMA,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 07:49:52,,1321256937,7/12/2014 07:49:28,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,glial elements with continuing DEDIFFERENTIATION.,133-142-147-158-127,72-98-109-127-133-124,GLIOBLASTOMA neoplastic transformation of glial elements,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 08:11:33,,1321264019,7/12/2014 08:09:08,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION.,158,72,GLIOBLASTOMA,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 08:16:42,,1321265331,7/12/2014 08:16:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION.,158,72,GLIOBLASTOMA,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 08:26:39,,1321268813,7/12/2014 08:26:33,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,elements with continuing DEDIFFERENTIATION.,133-142-147-158,49-62-67-72-85-93-98,pathogenetic view that GLIOBLASTOMA results from neoplastic,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 08:35:04,,1321271708,7/12/2014 08:34:55,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION.,158,72,GLIOBLASTOMA,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568379,7/12/2014 08:43:33,,1321274107,7/12/2014 08:43:12,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,158,72,,,175,84,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION.,158,72,GLIOBLASTOMA,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation.,158,72,158,72,175,84,1,RO-disease_has_finding,901970,The results of modern neuro-oncology support the pathogenetic view that glioblastoma results from neoplastic transformation of glial elements with continuing dedifferentiation,dedifferentiation,glioblastoma
502568380,7/12/2014 07:20:48,,1321247709,7/12/2014 07:20:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,chronic renal insufficiency and HYPERTENSION,58-66-72-86-90,141-154-161-167-177-180-188-193-203-207,HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 07:28:43,,1321250760,7/12/2014 07:28:18,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,90,141-154,HYPERTENSIVE CRISIS,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 07:29:47,,1321251096,7/12/2014 07:29:29,prodege,1.0,6316959,GBR,"","",87.112.13.121,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,90,141-154,HYPERTENSIVE CRISIS,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 07:40:40,,1321254271,7/12/2014 07:40:18,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,90,141-154,HYPERTENSIVE CRISIS,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 07:48:23,,1321256525,7/12/2014 07:47:55,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,chronic renal HYPERTENSION,58-90-66,141-154,HYPERTENSIVE CRISIS,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 08:10:08,,1321263627,7/12/2014 08:09:15,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,chronic renal insufficiency and HYPERTENSION,58-66-72-90-86,58-66-72-86-90-129-139-141-154-161-167-177-180,chronic renal insufficiency and hypertension developed a HYPERTENSIVE CRISIS after cessation of therapy,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 08:20:46,,1321266694,7/12/2014 08:20:43,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,renal insufficiency and HYPERTENSION for several years,66-72-86-90-103-107-115,125-129-139-141-154-161-167-177,who developed a HYPERTENSIVE CRISIS after cessation of,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 08:25:51,,1321268442,7/12/2014 08:25:47,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,renal insufficiency and HYPERTENSION for several years,66-72-86-90-103-107-115,125-129-139-141-154-161-167-177,who developed a HYPERTENSIVE CRISIS after cessation of,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 08:30:08,,1321270136,7/12/2014 08:29:46,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,90,141-154,HYPERTENSIVE CRISIS,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568380,7/12/2014 08:49:56,,1321276206,7/12/2014 08:49:48,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,90,141,,,102,160,HYPERTENSION,HYPERTENSIVE CRISIS,chronic renal insufficiency and HYPERTENSION for several years,66-72-86-90-103-107-115-58,125-129-139-141-154-161-167-177-180,who developed a HYPERTENSIVE CRISIS after cessation of therapy,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol.,90,141 154,90,141,102,160,1,RO-disease_has_finding,901968,The case is presented of a 49-year-old female who had had chronic renal insufficiency and hypertension for several years and who developed a hypertensive crisis after cessation of therapy with clonidine and nadolol,hypertension,hypertensive crisis
502568381,7/12/2014 07:44:18,,1321255282,7/12/2014 07:43:35,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,191,133,,,198,141,VESSELS,ISCHEMIA,VESSELS,191,133,ISCHEMIA,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 07:48:45,,1321256646,7/12/2014 07:48:19,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,191,133,,,198,141,VESSELS,ISCHEMIA,VESSELS,191,133,ISCHEMIA,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 07:51:36,,1321257590,7/12/2014 07:51:11,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,191,133,,,198,141,VESSELS,ISCHEMIA,VESSELS,191,133,ISCHEMIA,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 07:52:09,,1321257771,7/12/2014 07:51:27,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,191,133,,,198,141,VESSELS,ISCHEMIA,VESSELS,191,133,ISCHEMIA,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 07:55:14,,1321258927,7/12/2014 07:54:46,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,191,133,,,198,141,VESSELS,ISCHEMIA,VESSELS,191,133,ISCHEMIA,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 08:12:15,,1321264207,7/12/2014 08:11:53,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,191,133,,,198,141,VESSELS,ISCHEMIA,of small terminal VESSELS in the deep areas of brain.,173-176-182-191-199-202-206-211-217-224,116-127-130-133-142-149-152-164-173-176-182-191,determined by an ISCHEMIA caused by obstructive diseases of small terminal vessels,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 08:15:22,,1321264957,7/12/2014 08:15:04,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,191,133,,,198,141,VESSELS,ISCHEMIA,terminal VESSELS,182-191,133,ISCHEMIA,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 08:32:58,,1321271083,7/12/2014 08:32:44,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,191,133,,,198,141,VESSELS,ISCHEMIA,terminal VESSELS,182-191,133,ISCHEMIA,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 08:47:14,,1321275236,7/12/2014 08:47:08,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,191,133,,,198,141,VESSELS,ISCHEMIA,of small terminal VESSELS in the deep areas,173-176-182-191-199-202-206-211,116-127-130-133-142-149-152-112,are determined by an ISCHEMIA caused by obstructive,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568381,7/12/2014 08:56:13,,1321278244,7/12/2014 08:55:32,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,191,133,,,198,141,VESSELS,ISCHEMIA,small terminal VESSELS in the deep areas of the brain.,176-182-191-199-202-206-211-217-220-224,133-142-149-152-164-173-176-182-191-199-202-206-211-217-220-224,ISCHEMIA caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain.,191,133,191,133,198,141,1,RO-has_finding_site,905412,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ischemia caused by obstructive diseases of small terminal vessels in the deep areas of the brain,vessels,ischemia
502568382,7/12/2014 07:11:32,,1321244896,7/12/2014 07:11:06,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,67,77,,,73,87,NUMBER,SALMONELLA,groups in the NUMBER of Salmonella,53-60-63-67-74-77,63-67-74-77-88-91-95-101,the number of SALMONELLA in the cecal contents,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 07:34:27,,1321252616,7/12/2014 07:33:50,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,67,77,,,73,87,NUMBER,SALMONELLA,NUMBER Salmonella,67-77,77,SALMONELLA,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 07:41:05,,1321254369,7/12/2014 07:40:42,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,67,77,,,73,87,NUMBER,SALMONELLA,NUMBER,67,77,SALMONELLA,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 07:55:32,,1321259006,7/12/2014 07:54:59,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,67,77,,,73,87,NUMBER,SALMONELLA,NUMBER,67,77,SALMONELLA,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 08:31:19,,1321270571,7/12/2014 08:30:32,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,67,77,,,73,87,NUMBER,SALMONELLA,NUMBER,67,77,SALMONELLA,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 08:46:13,,1321274889,7/12/2014 08:45:29,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,67,77,,,73,87,NUMBER,SALMONELLA,four groups in the NUMBER of Salmonella in,53-60-63-67-74-77-88-48,53-63-67-74-77-88-91-95-60,groups in the number of SALMONELLA in the cecal,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 08:55:31,,1321277996,7/12/2014 08:54:43,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,67,77,,,73,87,NUMBER,SALMONELLA,NUMBER of Salmonella,67-74-77,77,SALMONELLA,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 08:59:18,,1321279243,7/12/2014 08:58:21,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,67,77,,,73,87,NUMBER,SALMONELLA,NUMBER,67,77,SALMONELLA,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 08:59:45,,1321279408,7/12/2014 08:58:51,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,67,77,,,73,87,NUMBER,SALMONELLA,NUMBER of Salmonella,67-74-77,77,SALMONELLA,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568382,7/12/2014 09:04:34,,1321281154,7/12/2014 09:02:14,neodev,1.0,20929875,USA,MA,Boston,71.174.188.90,67,77,,,73,87,NUMBER,SALMONELLA,NUMBER of Salmonella,67-74-77,77,SALMONELLA,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age.,67,77,67,77,73,87,-1,RO-has_causative_agent,903940,There were no significant differences among the four groups in the number of Salmonella in the cecal contents or in the number of cecal-culture-positive chicks on day 10 post-challenge at 15 days of age,number,Salmonella
502568383,7/12/2014 07:15:47,,1321246130,7/12/2014 07:14:53,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,63,13,,,68,24,BRAIN,ANENCEPHALY,BRAIN,63,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 07:34:19,,1321252549,7/12/2014 07:34:02,prodege,1.0,6316959,GBR,"","",87.112.13.121,63,13,,,68,24,BRAIN,ANENCEPHALY,BRAIN,63,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 07:38:22,,1321253643,7/12/2014 07:38:06,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,63,13,,,68,24,BRAIN,ANENCEPHALY,BRAIN,63,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 07:41:26,,1321254458,7/12/2014 07:41:08,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,63,13,,,68,24,BRAIN,ANENCEPHALY,BRAIN,63,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 07:50:50,,1321257317,7/12/2014 07:50:28,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,63,13,,,68,24,BRAIN,ANENCEPHALY,most of their BRAIN and die within,49-54-57-63-69-73-77,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 07:52:20,,1321257844,7/12/2014 07:51:58,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,63,13,,,68,24,BRAIN,ANENCEPHALY,BRAIN,63,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 08:17:13,,1321265454,7/12/2014 08:17:07,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,63,13,,,68,24,BRAIN,ANENCEPHALY,most of their BRAIN and die within,49-54-57-63-69-73-77,0-8-13-25-29-34,Infants with ANENCEPHALY are born without,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 08:20:02,,1321266406,7/12/2014 08:19:45,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,63,13,,,68,24,BRAIN,ANENCEPHALY,BRAIN,63,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 08:31:49,,1321270724,7/12/2014 08:31:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,63,13,,,68,24,BRAIN,ANENCEPHALY,BRAIN,63,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568383,7/12/2014 08:34:54,,1321271669,7/12/2014 08:34:44,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,63,13,,,68,24,BRAIN,ANENCEPHALY,BRAIN,63,13,ANENCEPHALY,Infants with anencephaly are born without all or most of their brain and die within a few days of life.,63,13,63,13,68,24,1,RO-has_finding_site,905480,Infants with anencephaly are born without all or most of their brain and die within a few days of life,brain,anencephaly
502568384,7/12/2014 07:13:49,,1321245549,7/12/2014 07:12:51,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and MEDULLARY THYROID CARCINOMA (MTC1) familial cancer syndromes.,127-136-146-156-161-163-170-174-181-185-195-203-213-220-229-236,127-136-156-161-163-170-174-181-185-195-203-213-146,multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1),"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 07:39:18,,1321253880,7/12/2014 07:38:46,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,MEDULLARY THYROID CARCINOMA (MTC1),185-195-203-213,127-136-146-156-161-163-170-174,multiple endocrine neoplasia type 2 (MEN2A and MEN2B),"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 07:42:12,,1321254623,7/12/2014 07:41:37,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,MEDULLARY THYROID CARCINOMA,185-195-203,174,MEN2B),"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 07:46:35,,1321255959,7/12/2014 07:46:00,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,MEDULLARY THYROID CARCINOMA (MTC1) cancer syndromes.,185-195-203-213-229-236,136-146-156-161-163-174,endocrine neoplasia type 2 (MEN2A MEN2B),"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 07:47:10,,1321256137,7/12/2014 07:46:39,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,MEDULLARY THYROID CARCINOMA,185-195-203,174,MEN2B),"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 07:54:38,,1321258696,7/12/2014 07:53:36,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,MEDULLARY THYROID CARCINOMA,185-195-203,174,MEN2B),"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 08:11:35,,1321264021,7/12/2014 08:10:40,prodege,1.0,21891314,AUS,07,Glen Iris,58.6.248.249,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,MEDULLARY THYROID CARCINOMA,185-195-203,174-185-195-203,MEN2B) medullary thyroid carcinoma,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 08:12:41,,1321264299,7/12/2014 08:12:16,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,type 2 (MEN2A and MEN2B) and MEDULLARY THYROID CARCINOMA (MTC1) syndromes.,156-161-163-170-174-181-185-195-203-213-236,161-163-170-174-181-185-195-203-213,2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1),"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 08:20:39,,1321266647,7/12/2014 08:20:36,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,and MEN2B) and MEDULLARY THYROID CARCINOMA familial cancer,170-174-181-185-195-203-220-229,161-163-170-174-181-185-195,2 (MEN2A and MEN2B) and medullary thyroid,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568384,7/12/2014 08:24:23,,1321267873,7/12/2014 08:24:16,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,185,174,,,212,179,MEDULLARY THYROID CARCINOMA,MEN2B,and MEN2B) and MEDULLARY THYROID CARCINOMA familial cancer,170-174-181-185-195-203-220-229,161-163-170-174-181-185-195,2 (MEN2A and MEN2B) and medullary thyroid,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes.",185 195 203,174,185,174,212,179,-1,RO-has_manifestation,906397,"The genetic loci RET, D10S94, and D10S102 from human chromosome 10q11.2 are very closely linked to a locus responsible for the multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and medullary thyroid carcinoma (MTC1) familial cancer syndromes",medullary thyroid carcinoma,MEN2B
502568385,7/12/2014 07:26:42,,1321250042,7/12/2014 07:26:20,prodege,1.0,6316959,GBR,"","",87.112.13.121,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,BENIGN TERTIAN MALARIA,70-77-85,118,PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 07:34:16,,1321252530,7/12/2014 07:33:24,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,BENIGN TERTIAN MALARIA,70-77-85,118,PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 07:35:23,,1321252835,7/12/2014 07:34:49,elite,1.0,28322695,GBR,G8,Dewsbury,217.44.206.25,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,BENIGN TERTIAN MALARIA,70-77-85,118,PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 07:36:18,,1321253100,7/12/2014 07:35:58,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,BENIGN TERTIAN MALARIA,70-77-85,118,PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 07:36:36,,1321253159,7/12/2014 07:35:59,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,4 - aminoquinolines BENIGN TERTIAN MALARIA primaquine,22-23-24-70-77-85-118,70-77-85-118,benign tertian malaria PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 07:44:02,,1321255221,7/12/2014 07:43:37,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,latent BENIGN TERTIAN MALARIA,63-70-77-85,118,PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 07:44:07,,1321255244,7/12/2014 07:43:50,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,latent BENIGN TERTIAN MALARIA,63-70-77-85,118,PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 08:26:26,,1321268736,7/12/2014 08:26:21,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,"protection against latent BENIGN TERTIAN MALARIA is noted, and",44-55-63-70-77-85-93-96-103,107-111-115-118-129-132,the use of PRIMAQUINE is recommended.,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 08:37:48,,1321272511,7/12/2014 08:37:37,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,latent BENIGN TERTIAN MALARIA,63-70-77-85,118,PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568385,7/12/2014 08:39:21,,1321272955,7/12/2014 08:38:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,70,118,,,92,128,BENIGN TERTIAN MALARIA,PRIMAQUINE,BENIGN TERTIAN MALARIA,70-77-85,118,PRIMAQUINE,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended.",70 77 85,118,70,118,92,128,1,RO-may_prevent,907114,"The inadequacy of the 4-aminoquinolines for protection against latent benign tertian malaria is noted, and the use of primaquine is recommended",benign tertian malaria,primaquine
502568386,7/12/2014 07:31:57,,1321251768,7/12/2014 07:31:06,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 07:36:22,,1321253111,7/12/2014 07:35:55,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 07:38:10,,1321253564,7/12/2014 07:37:53,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 07:44:55,,1321255486,7/12/2014 07:44:29,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 07:50:30,,1321257228,7/12/2014 07:49:13,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 07:57:04,,1321259539,7/12/2014 07:56:43,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 08:17:05,,1321265437,7/12/2014 08:16:38,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 08:19:34,,1321266249,7/12/2014 08:19:19,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,"cell aplasia), 2 THROMBOCYTOPENIA and 2 agranulocytosis",130-135-145-147-164-168-170,61-66-74-76-90-92,"with anemia, 7 PANCYTOPENIA, 2 anemia","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 08:30:05,,1321270120,7/12/2014 08:29:03,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568386,7/12/2014 08:30:31,,1321270262,7/12/2014 08:30:10,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,147,76,,,163,88,THROMBOCYTOPENIA,PANCYTOPENIA,THROMBOCYTOPENIA,147,76,"PANCYTOPENIA,","They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia.",147,76,147,76,163,88,-1,RO-has_definitional_manifestation,904526,"They were consisted of 14 agranulocytosis, 9 agranulocytosis with anemia, 7 pancytopenia, 2 anemia (hemolytic anemia and pure red cell aplasia), 2 thrombocytopenia and 2 agranulocytosis with thrombocytopenia",thrombocytopenia,pancytopenia
502568387,7/12/2014 07:14:14,,1321245628,7/12/2014 07:13:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,oral cladribine for relapsing MULTIPLE SCLEROSIS.,74-85-89-99-108-69,69-74-85-89-99-108,oral CLADRIBINE for relapsing multiple sclerosis.,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 07:34:00,,1321252463,7/12/2014 07:33:30,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,relapsing MULTIPLE SCLEROSIS.,99-108-89,69-74,oral CLADRIBINE,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 07:41:07,,1321254377,7/12/2014 07:40:52,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,MULTIPLE SCLEROSIS.,99-108,74,CLADRIBINE,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 07:53:44,,1321258340,7/12/2014 07:53:21,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,relapsing MULTIPLE SCLEROSIS.,89-99-108,74,CLADRIBINE,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 08:02:05,,1321261226,7/12/2014 08:01:52,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,MULTIPLE SCLEROSIS.,99-108,69-74,oral CLADRIBINE,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 08:13:43,,1321264590,7/12/2014 08:13:23,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,placebo controlled trial of oral cladribine for relapsing MULTIPLE SCLEROSIS.,41-49-60-69-74-85-89-99-108-66,41-60-66-69-74-85-89-99-108-49,placebo controlled trial of oral CLADRIBINE for relapsing multiple sclerosis.,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 08:48:54,,1321275858,7/12/2014 08:48:49,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,oral cladribine for relapsing MULTIPLE SCLEROSIS.,74-85-89-99-108-69,60-66-69-74-85-89-99-49,controlled trial of oral CLADRIBINE for relapsing multiple,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 08:50:25,,1321276387,7/12/2014 08:50:11,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,MULTIPLE SCLEROSIS.,99-108,74-89-99-108,CLADRIBINE relapsing multiple sclerosis.,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 08:55:22,,1321277977,7/12/2014 08:55:02,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,MULTIPLE SCLEROSIS.,99-108,74,CLADRIBINE,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568387,7/12/2014 09:04:06,,1321281061,7/12/2014 09:03:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,99,74,,,117,84,MULTIPLE SCLEROSIS,CLADRIBINE,relapsing MULTIPLE SCLEROSIS.,99-108-89,69-74,oral CLADRIBINE,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.,99 108,74,99,74,117,84,1,RO-may_treat,907766,New Reference of Interest  2010-02-04  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,multiple sclerosis,cladribine
502568388,7/12/2014 07:21:24,,1321247912,7/12/2014 07:20:50,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,95,26,,,101,38,CARIES,FLUORIDE ION,to prevent CARIES,84-87-95,26-35-39,FLUORIDE ION concentration,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 07:39:21,,1321253888,7/12/2014 07:39:00,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,95,26,,,101,38,CARIES,FLUORIDE ION,CARIES,95,26-35,FLUORIDE ION,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 07:41:32,,1321254478,7/12/2014 07:41:02,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,95,26,,,101,38,CARIES,FLUORIDE ION,CARIES,95,26-35-39,FLUORIDE ION concentration,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 07:41:54,,1321254550,7/12/2014 07:41:37,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,95,26,,,101,38,CARIES,FLUORIDE ION,CARIES,95,26-35,FLUORIDE ION,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 08:01:52,,1321261164,7/12/2014 08:00:34,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,95,26,,,101,38,CARIES,FLUORIDE ION,CARIES,95,26-35,FLUORIDE ION,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 08:19:20,,1321266172,7/12/2014 08:19:04,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,95,26,,,101,38,CARIES,FLUORIDE ION,CARIES,95,26-35,FLUORIDE ION,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 08:26:51,,1321268887,7/12/2014 08:26:46,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,95,26,,,101,38,CARIES,FLUORIDE ION,) to prevent CARIES only in very,82-84-87-95-102-107-110,12-17-22-26-35-39-53-56,show that the FLUORIDE ION concentration is sufficient,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 08:35:38,,1321271895,7/12/2014 08:35:21,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,95,26,,,101,38,CARIES,FLUORIDE ION,CARIES,95,26-35,FLUORIDE ION,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 08:41:16,,1321273529,7/12/2014 08:40:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,95,26,,,101,38,CARIES,FLUORIDE ION,CARIES,95,26-35,FLUORIDE ION,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568388,7/12/2014 08:52:44,,1321277086,7/12/2014 08:51:42,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,95,26,,,101,38,CARIES,FLUORIDE ION,CARIES,95,26-35-39-53-56-67-72-76-80-81-82-71,FLUORIDE ION concentration is sufficient (0.7 - 1.0 ppm F - ),"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",95,26 35,95,26,101,38,1,RO-may_prevent,907385,"The results show that the fluoride ion concentration is sufficient (0.7-1.0 ppm F-) to prevent caries only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria",caries,fluoride ion
502568389,7/12/2014 07:12:08,,1321245034,7/12/2014 07:11:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,the metabolism of ETHANOL lead to glutathione oxidation,158-162-173-176-184-189-192-204,265-271-279-282,TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 07:25:48,,1321249668,7/12/2014 07:24:55,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,ETHANOL,176,265-271-279-282,TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 07:30:49,,1321251431,7/12/2014 07:30:37,prodege,1.0,6316959,GBR,"","",87.112.13.121,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,ETHANOL,176,265-271-279-282,TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 07:39:19,,1321253886,7/12/2014 07:39:07,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,ETHANOL,176,265-271-279-282,TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 07:49:27,,1321256818,7/12/2014 07:48:54,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,ETHANOL lead to glutathione oxidation lipid peroxidation,176-184-189-192-204-218-224,265-271-279-282,TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 07:49:59,,1321256991,7/12/2014 07:49:38,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,ETHANOL,176,265-271-279-282,TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 08:02:31,,1321261361,7/12/2014 08:02:06,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,ETHANOL,176,265-271-279-282,TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 08:19:47,,1321266326,7/12/2014 08:19:09,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,Ethanol induced depletion of hepatic glutathione ETHANOL,0-8-16-26-29-37-176,0-8-16-26-29-37-265-271-279-282,Ethanol induced depletion of hepatic glutathione TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 08:25:15,,1321268190,7/12/2014 08:25:10,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,the metabolism of ETHANOL lead to glutathione,158-162-173-176-184-189-192,245-257-261-265-271-279-282,responsible for the TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568389,7/12/2014 08:48:41,,1321275798,7/12/2014 08:48:36,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,176,265,,,183,289,ETHANOL,TOXIC EFFECTS OF ETHANOL,the metabolism of ETHANOL lead to glutathione oxidation,158-162-173-176-184-189-192-204,245-257-261-265-271-279-282-237,and responsible for the TOXIC EFFECTS OF ETHANOL.,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol.,176,265 271 279 282,176,265,183,289,-1,RO-has_causative_agent,903569,Ethanol-induced depletion of hepatic glutathione has been construed as evidence supporting the hypothesis that reactive oxygen intermediates generated during the metabolism of ethanol lead to glutathione oxidation and lipid peroxidation and are responsible for the toxic effects of ethanol,ethanol,toxic effects of ethanol
502568390,7/12/2014 07:26:13,,1321249854,7/12/2014 07:25:49,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,DISSEMINATED INTRAVASCULAR COAGULATION,61-74-88,103-109-123,ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 07:26:24,,1321249959,7/12/2014 07:25:57,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in acute promyelocytic leukemia.,37-49-58-61-74-88-100-103-109-123,74-88-100-103-109-123,intravascular coagulation in ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 07:33:41,,1321252372,7/12/2014 07:33:20,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,DISSEMINATED INTRAVASCULAR COAGULATION,61-74-88,103-109-123,ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 07:33:49,,1321252405,7/12/2014 07:33:28,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,DISSEMINATED INTRAVASCULAR COAGULATION,61-74-88,103-109-123,ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 07:44:17,,1321255292,7/12/2014 07:42:54,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,DISSEMINATED INTRAVASCULAR COAGULATION,61-74-88,103-109-123,ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 07:54:08,,1321258446,7/12/2014 07:53:45,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,DISSEMINATED INTRAVASCULAR COAGULATION,61-74-88,103-109-123,ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 07:55:04,,1321258879,7/12/2014 07:54:30,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in acute promyelocytic leukemia.,37-49-58-61-74-88-100-103-109-123,37-49-58-74-88-100-103-109-123-61,Coagulation patterns of disseminated intravascular coagulation in ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 08:17:27,,1321265532,7/12/2014 08:17:22,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in acute promyelocytic,37-49-58-61-74-88-100-103-109,74-88-100-103-109-123,intravascular coagulation in ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 08:20:11,,1321266454,7/12/2014 08:19:49,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,DISSEMINATED INTRAVASCULAR COAGULATION acute promyelocytic leukemia.,61-74-88-103-109-123,103-109-123,ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568390,7/12/2014 08:21:36,,1321266993,7/12/2014 08:20:54,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,61,103,,,99,131,DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in acute promyelocytic leukemia.,37-49-58-61-74-88-100-103-109-123,74-88-100-103-109-123-37,Coagulation intravascular coagulation in ACUTE PROMYELOCYTIC LEUKEMIA.,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.",61 74 88,103 109 123,61,103,99,131,-1,RO-disease_may_have_finding,902751,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia",disseminated intravascular coagulation,acute promyelocytic leukemia
502568391,7/12/2014 07:24:25,,1321249136,7/12/2014 07:23:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,STRABISMIC AMBLYOPIA,184-195,222-236-240,anisometropia and STRABISMUS.,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 07:34:43,,1321252673,7/12/2014 07:34:28,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,STRABISMIC AMBLYOPIA,184-195,222-240,anisometropia STRABISMUS.,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 07:38:17,,1321253620,7/12/2014 07:37:55,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,STRABISMIC AMBLYOPIA,184-195,240,STRABISMUS.,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 07:41:25,,1321254447,7/12/2014 07:40:15,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,"anisometropic amblyopia, STRABISMIC AMBLYOPIA",148-162-184-195,148-162-184-222-240-195,"anisometropic amblyopia, strabismic amblyopia anisometropia STRABISMUS.","Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 07:48:08,,1321256468,7/12/2014 07:47:56,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,STRABISMIC AMBLYOPIA,184-195,240,STRABISMUS.,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 07:56:13,,1321259265,7/12/2014 07:56:00,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,STRABISMIC AMBLYOPIA,184-195,240,STRABISMUS.,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 07:57:22,,1321259634,7/12/2014 07:56:43,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,STRABISMIC AMBLYOPIA,184-195,240,STRABISMUS.,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 08:33:51,,1321271337,7/12/2014 08:33:15,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,STRABISMIC AMBLYOPIA,184-195,240,STRABISMUS.,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 08:49:42,,1321276115,7/12/2014 08:49:36,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,"amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both",162-173-179-184-195-205-209-212-217,217-222-236-240-212,with both anisometropia and STRABISMUS.,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568391,7/12/2014 08:49:47,,1321276141,7/12/2014 08:49:25,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,184,240,,,204,250,STRABISMIC AMBLYOPIA,STRABISMUS,"anisometropic amblyopia, STRABISMIC AMBLYOPIA",148-162-184-195,148-162-184-195-240,"anisometropic amblyopia, strabismic amblyopia STRABISMUS.","Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus.",184 195,240,184,240,204,250,-1,RO-cause_of,900016,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with strabismic amblyopia and 10 with both anisometropia and strabismus",strabismic amblyopia,strabismus
502568392,7/12/2014 07:39:44,,1321253974,7/12/2014 07:39:22,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,PARKINSONISM,240,137-149-162,PROGRESSIVE SUPRANUCLEAR PALSY,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 07:40:30,,1321254219,7/12/2014 07:40:12,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,PARKINSONISM,240,137-149-162,PROGRESSIVE SUPRANUCLEAR PALSY,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 08:02:44,,1321261441,7/12/2014 08:01:52,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,PARKINSONISM,240,137-149-162,PROGRESSIVE SUPRANUCLEAR PALSY,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 08:18:12,,1321265804,7/12/2014 08:17:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,PARKINSONISM,240,115-122-130-137-149-162-175-188,"Pick's disease (PiD), PROGRESSIVE SUPRANUCLEAR PALSY corticobasal degeneration","Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 08:20:45,,1321266693,7/12/2014 08:20:12,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,Alzheimer's PARKINSONISM,57-240,115-122-130-137-149-162-175-188-57,"Alzheimer's Pick's disease (PiD), PROGRESSIVE SUPRANUCLEAR PALSY corticobasal degeneration","Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 08:25:45,,1321268397,7/12/2014 08:25:41,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,frontotemporal dementia and PARKINSONISM linked to chromosome,212-227-236-240-253-260-263,115-122-130-137-149-162-175-188,"Pick's disease (PiD), PROGRESSIVE SUPRANUCLEAR PALSY corticobasal degeneration","Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 08:35:17,,1321271777,7/12/2014 08:34:45,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,PARKINSONISM,240,137-149-162,PROGRESSIVE SUPRANUCLEAR PALSY,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 08:37:03,,1321272238,7/12/2014 08:36:46,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,PARKINSONISM,240,137-149-162,PROGRESSIVE SUPRANUCLEAR PALSY,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 08:46:27,,1321274956,7/12/2014 08:46:21,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,dementia and PARKINSONISM linked to chromosome,227-236-240-253-260-263,115-122-130-137-149-162-175,"Pick's disease (PiD), PROGRESSIVE SUPRANUCLEAR PALSY corticobasal","Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568392,7/12/2014 08:59:37,,1321279388,7/12/2014 08:59:19,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,240,137,,,252,167,PARKINSONISM,PROGRESSIVE SUPRANUCLEAR PALSY,frontotemporal dementia PARKINSONISM,212-227-240,115-122-130-137-149-162-175-188,"Pick's disease (PiD), PROGRESSIVE SUPRANUCLEAR PALSY corticobasal degeneration","Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17.",240,137 149 162,240,137,252,167,-1,RO-has_manifestation,906366,"Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17",parkinsonism,progressive supranuclear palsy
502568393,7/12/2014 07:33:27,,1321252284,7/12/2014 07:32:41,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,"DYSPLASIA II (moderate dysplasia),",101-111-114-124,71-81-83-89,"dysplasia I (MILD DYSPLASIA),","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 07:45:10,,1321255549,7/12/2014 07:44:03,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,DYSPLASIA II,101-111,71-81-83-89,"dysplasia I (MILD DYSPLASIA),","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 07:45:19,,1321255592,7/12/2014 07:44:56,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,"DYSPLASIA II (moderate dysplasia),",101-114-124-111,71-81-83-89,"dysplasia I (MILD DYSPLASIA),","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 07:50:11,,1321257083,7/12/2014 07:49:53,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,"dysplasia I (mild dysplasia), DYSPLASIA II",71-81-83-89-101-111,71-81-83-89-101-111,"dysplasia I (MILD DYSPLASIA), dysplasia II","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 08:20:11,,1321266455,7/12/2014 08:20:08,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,"I (mild dysplasia), DYSPLASIA II dysplasia),",81-83-89-101-111-124,71-81-83-89-101-111,"dysplasia I (MILD DYSPLASIA), dysplasia II","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 08:22:49,,1321267381,7/12/2014 08:22:32,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,"dysplasia I (mild dysplasia), DYSPLASIA II dysplasia),",71-81-83-89-101-111-124,71-81-83-89-101-111-191-178,"dysplasia I (MILD DYSPLASIA), dysplasia II carcinoma esophagus","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 08:31:32,,1321270653,7/12/2014 08:31:00,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,DYSPLASIA II,101-111,83-89,"(MILD DYSPLASIA),","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 08:43:12,,1321274011,7/12/2014 08:42:50,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,DYSPLASIA,101,89,"DYSPLASIA),","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 08:46:50,,1321275083,7/12/2014 08:46:42,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,"dysplasia I (mild dysplasia), DYSPLASIA II dysplasia),",81-83-89-101-111-124-71,71-81-83-89-101-111-63,"normal, dysplasia I (MILD DYSPLASIA), dysplasia II","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568393,7/12/2014 08:58:21,,1321278930,7/12/2014 08:56:14,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,101,84,,,110,98,DYSPLASIA,MILD DYSPLASIA,"DYSPLASIA II (moderate dysplasia),",101-111-114-124,71-81-83-89,"dysplasia I (MILD DYSPLASIA),","According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC.",101,89,101,84,110,98,-1,RO-disease_has_finding,901640,"According to pathological characteristics, these 5 stages were normal, dysplasia I (mild dysplasia), dysplasia II (moderate dysplasia), carcinoma in situ (CIS) and squamous cell carcinoma of esophagus (SCC",dysplasia,mild dysplasia
502568394,7/12/2014 07:28:01,,1321250531,7/12/2014 07:27:23,prodege,1.0,6316959,GBR,"","",87.112.13.121,53,32,,,56,37,DLE,LUPUS,Discoid lupus erythematosus (DLE):,32-38-52-24,32,LUPUS,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 07:33:19,,1321252259,7/12/2014 07:32:41,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,53,32,,,56,37,DLE,LUPUS,"DLE,",60,32,LUPUS,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 07:38:05,,1321253549,7/12/2014 07:37:13,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,53,32,,,56,37,DLE,LUPUS,Discoid lupus erythematosus (DLE):,24-32-38-52,24-32-38-52,Discoid LUPUS erythematosus (DLE):,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 07:42:48,,1321254838,7/12/2014 07:42:21,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,53,32,,,56,37,DLE,LUPUS,"DLE,",60,32,LUPUS,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 07:47:32,,1321256208,7/12/2014 07:47:04,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,53,32,,,56,37,DLE,LUPUS,"LUPUS Discoid lupus erythematosus (DLE): DLE, chronic cutaneous lupus erythematosus,",17-24-32-38-52-60-87-95-105-111,17-24-32-38-52,LUPUS Discoid LUPUS erythematosus (DLE):,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 07:52:25,,1321257871,7/12/2014 07:51:53,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,53,32,,,56,37,DLE,LUPUS,Discoid lupus erythematosus (DLE):,24-32-38-52,24-32-38-52,Discoid LUPUS erythematosus (DLE):,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 08:17:53,,1321265668,7/12/2014 08:17:43,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,53,32,,,56,37,DLE,LUPUS,"lupus erythematosus (DLE): DLE, also sometimes",32-38-52-60-65-70,14-17-24-32-38-60,"OF LUPUS Discoid LUPUS erythematosus DLE,","VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 08:34:27,,1321271522,7/12/2014 08:34:00,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,53,32,,,56,37,DLE,LUPUS,"Discoid lupus erythematosus DLE,",32-38-60-24,24-32-38-60,"Discoid LUPUS erythematosus DLE,","VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 08:50:03,,1321276244,7/12/2014 08:49:57,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,53,32,,,56,37,DLE,LUPUS,"lupus erythematosus (DLE): DLE, also sometimes called",32-38-52-60-65-70-80,14-17-24-32-38-60-65,"OF LUPUS Discoid LUPUS erythematosus DLE, also","VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568394,7/12/2014 08:57:33,,1321278712,7/12/2014 08:57:10,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,53,32,,,56,37,DLE,LUPUS,lupus erythematosus (DLE):,32-38-52,17-24-32-38,LUPUS Discoid LUPUS erythematosus,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement.",,32,53,32,56,37,-1,RO-cause_of,900248,"VARIANT FORMS OF LUPUS  Discoid lupus erythematosus (DLE):  DLE, also sometimes called chronic cutaneous lupus erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic involvement",DLE,lupus
502568395,7/12/2014 07:33:23,,1321252279,7/12/2014 07:32:58,prodege,1.0,6316959,GBR,"","",87.112.13.121,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GISTS),54-71-79-86,54-71-79-86,GASTROINTESTINAL STROMAL TUMORS (GISTs),"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 07:37:54,,1321253476,7/12/2014 07:37:26,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,(GISTS),86,54-71-79,GASTROINTESTINAL STROMAL TUMORS,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 07:38:45,,1321253742,7/12/2014 07:38:23,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GISTS),54-71-79-86,54-71-79-86,GASTROINTESTINAL STROMAL TUMORS (GISTs),"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 07:42:21,,1321254665,7/12/2014 07:41:50,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,(GISTS),86,54-71-79,GASTROINTESTINAL STROMAL TUMORS,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 07:48:18,,1321256520,7/12/2014 07:47:34,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GISTS),54-71-79-86,54-71-79-86,GASTROINTESTINAL STROMAL TUMORS (GISTs),"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 07:56:31,,1321259354,7/12/2014 07:55:44,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GISTS),54-71-79-86,54-71-79-86,GASTROINTESTINAL STROMAL TUMORS (GISTs),"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 08:14:00,,1321264673,7/12/2014 08:13:46,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GISTS),71-79-86,37-54-71-79-86,the GASTROINTESTINAL STROMAL TUMORS (GISTs),"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 08:24:02,,1321267735,7/12/2014 08:23:47,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GISTS) highlighted the urgency,71-79-86-94-106-110,54-71-79,GASTROINTESTINAL STROMAL TUMORS,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 08:32:43,,1321271054,7/12/2014 08:32:30,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GISTS),71-79-86-54,54-71-79,GASTROINTESTINAL STROMAL TUMORS,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568395,7/12/2014 08:37:55,,1321272519,7/12/2014 08:34:49,neodev,1.0,20929875,USA,MA,Boston,71.174.188.90,87,54,,,92,85,GISTS,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GISTS),71-79-86,54-71-79-86,GASTROINTESTINAL STROMAL TUMORS (GISTs),"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target.",,54 71 79,87,54,92,85,-1,RO-has_manifestation,906265,"The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target",GISTs,gastrointestinal stromal tumors
502568396,7/12/2014 07:19:42,,1321247365,7/12/2014 07:18:48,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,Herbal therapy for treating RHEUMATOID ARTHRITIS,349-356-364-368-377-388,307-318-323-327-338,Injectable GOLD for rheumatoid arthritis,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 07:34:50,,1321252703,7/12/2014 07:34:27,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,RHEUMATOID ARTHRITIS,377-388,318,GOLD,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 07:57:50,,1321259719,7/12/2014 07:56:50,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,RHEUMATOID ARTHRITIS,377-388,318-323,GOLD for,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 08:17:21,,1321265496,7/12/2014 08:16:05,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,therapy for treating RHEUMATOID ARTHRITIS Folic acid and,356-364-368-377-388-399-405-410,285-296-307-318-323-327-338,rheumatoid arthritis Injectable GOLD for rheumatoid arthritis,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 08:25:33,,1321268330,7/12/2014 08:25:29,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,therapy for treating RHEUMATOID ARTHRITIS Folic acid and,356-364-368-377-388-399-405-410,285-296-307-318-323-327-338,rheumatoid arthritis Injectable GOLD for rheumatoid arthritis,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 08:39:41,,1321273041,7/12/2014 08:39:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,RHEUMATOID ARTHRITIS,377-388,318,GOLD,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 08:46:33,,1321274992,7/12/2014 08:46:27,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,therapy for treating RHEUMATOID ARTHRITIS Folic acid and folinic,356-364-368-377-388-399-405-410-414,285-296-307-318-323-327-338-349,rheumatoid arthritis Injectable GOLD for rheumatoid arthritis Herbal,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 08:53:23,,1321277372,7/12/2014 08:52:50,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,RHEUMATOID ARTHRITIS Folic,377-388-399,318,GOLD,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 09:03:09,,1321280718,7/12/2014 09:01:29,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,RHEUMATOID ARTHRITIS,377-388,318-323-327-338-307,Injectable GOLD for rheumatoid arthritis,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568396,7/12/2014 09:05:04,,1321281302,7/12/2014 09:02:37,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,377,318,,,397,322,RHEUMATOID ARTHRITIS,GOLD,RHEUMATOID ARTHRITIS,377-388,307-318-323-327-338,Injectable GOLD for rheumatoid arthritis,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",377 388,318,377,318,397,322,1,RO-may_treat,907956,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate-term, low-dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  Injectable gold for rheumatoid arthritis  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis",rheumatoid arthritis,gold
502568397,7/12/2014 07:20:17,,1321247576,7/12/2014 07:19:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,66,112,,,73,126,STOMACH,GASTRIC CANCER,extensive intestinal metaplasia of the STOMACH,27-37-48-59-62-66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 07:35:09,,1321252783,7/12/2014 07:34:52,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,66,112,,,73,126,STOMACH,GASTRIC CANCER,STOMACH,66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 07:39:33,,1321253918,7/12/2014 07:39:19,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,66,112,,,73,126,STOMACH,GASTRIC CANCER,STOMACH,66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 07:46:37,,1321255971,7/12/2014 07:46:17,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,66,112,,,73,126,STOMACH,GASTRIC CANCER,STOMACH,66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 07:47:00,,1321256070,7/12/2014 07:46:37,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,66,112,,,73,126,STOMACH,GASTRIC CANCER,STOMACH,66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 07:52:54,,1321258043,7/12/2014 07:52:21,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,66,112,,,73,126,STOMACH,GASTRIC CANCER,intestinal metaplasia of the STOMACH,48-59-62-66-37,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 07:53:23,,1321258211,7/12/2014 07:53:09,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,66,112,,,73,126,STOMACH,GASTRIC CANCER,STOMACH,66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 08:14:49,,1321264839,7/12/2014 08:14:41,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,66,112,,,73,126,STOMACH,GASTRIC CANCER,metaplasia of the STOMACH,48-59-62-66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 08:33:47,,1321271318,7/12/2014 08:33:36,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,66,112,,,73,126,STOMACH,GASTRIC CANCER,STOMACH,66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568397,7/12/2014 08:34:48,,1321271639,7/12/2014 08:34:09,neodev,1.0,20929875,USA,MA,Boston,71.174.188.90,66,112,,,73,126,STOMACH,GASTRIC CANCER,STOMACH,66,112-120,GASTRIC CANCER.,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer.",66,112 120,66,112,73,126,1,RO-disease_has_primary_anatomic_site,902028,"However, the patients with extensive intestinal metaplasia of the stomach belong to the high risk group for the gastric cancer",stomach,gastric cancer
502568398,7/12/2014 07:39:37,,1321253942,7/12/2014 07:39:21,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 07:41:49,,1321254537,7/12/2014 07:40:59,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 07:45:59,,1321255792,7/12/2014 07:45:31,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,multiresistant strains of MYCOBACTERIUM TUBERCULOSIS,61-76-84-87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 07:49:56,,1321256968,7/12/2014 07:48:47,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 07:50:47,,1321257299,7/12/2014 07:50:21,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 08:19:03,,1321266052,7/12/2014 08:18:51,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 08:19:15,,1321266122,7/12/2014 08:19:13,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become,61-76-84-87-101-114-118-122,148-152-157-160-173-182-185,the care of TUBERCULOSIS patients in Sweden.,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 08:38:00,,1321272534,7/12/2014 08:37:50,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 08:38:38,,1321272679,7/12/2014 08:38:11,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568398,7/12/2014 08:59:31,,1321279324,7/12/2014 08:58:58,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,87,160,,,113,172,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,multiresistant strains of MYCOBACTERIUM TUBERCULOSIS,61-76-84-87-101,160,TUBERCULOSIS,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden.,87 101,160,87,160,113,172,-1,RO-has_causative_agent,903953,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of Mycobacterium tuberculosis has yet become a major problem in the care of tuberculosis patients in Sweden,Mycobacterium tuberculosis,tuberculosis
502568399,7/12/2014 07:28:00,,1321250530,7/12/2014 07:27:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"subsequent ALLERGIC REACTION,",41-52-61,87-91-99-108,the chronic ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 07:34:27,,1321252613,7/12/2014 07:33:55,elite,1.0,28322695,GBR,G8,Dewsbury,217.44.206.25,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"ALLERGIC REACTION,",52-61,91-99-108,chronic ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 07:37:39,,1321253380,7/12/2014 07:37:30,prodege,1.0,6316959,GBR,"","",87.112.13.121,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"ALLERGIC REACTION,",52-61,91-99-108,chronic ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 07:37:49,,1321253453,7/12/2014 07:37:17,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"ALLERGIC REACTION, chronic allergic state.",52-61-91-99-108,91-99-108,chronic ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 07:41:36,,1321254481,7/12/2014 07:41:21,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"ALLERGIC REACTION,",52-61,99-108,ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 07:47:35,,1321256232,7/12/2014 07:47:11,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"ALLERGIC REACTION,",52-61,99-108,ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 07:56:42,,1321259417,7/12/2014 07:56:24,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"ALLERGIC REACTION,",52-61,91-99-108,chronic ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 08:18:25,,1321265845,7/12/2014 08:18:13,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"ALLERGIC REACTION,",52-61,91-99-108,chronic ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 08:20:25,,1321266552,7/12/2014 08:20:23,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"of any subsequent ALLERGIC REACTION, contributing to the",34-37-41-52-61-71-84-87,84-87-91-99-108,to the chronic ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568399,7/12/2014 08:33:36,,1321271271,7/12/2014 08:33:25,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,52,99,,,69,113,ALLERGIC REACTION,ALLERGIC STATE,"ALLERGIC REACTION,",52-61,91-99-108,chronic ALLERGIC STATE.,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state.",52 61,99 108,52,99,69,113,-1,RO-cause_of,900317,"This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state",allergic reaction,allergic state
502568400,7/12/2014 07:12:50,,1321245248,7/12/2014 07:12:09,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,HEADACHE and cluster headache,40-49-53-61,0-4-15-18-26,The occurrence of CLUSTER HEADACHE,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 07:34:22,,1321252573,7/12/2014 07:33:20,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,HEADACHE cluster headache syndrome.,40-150-158-167,18-26-53-61,CLUSTER HEADACHE cluster headache,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 07:40:51,,1321254304,7/12/2014 07:40:32,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,HEADACHE,40,18-26,CLUSTER HEADACHE,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 07:42:13,,1321254629,7/12/2014 07:41:46,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,HEADACHE,40,18-26,CLUSTER HEADACHE,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 07:43:49,,1321255154,7/12/2014 07:41:57,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,sine HEADACHE,40-35,18-26,CLUSTER HEADACHE,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 07:52:33,,1321257914,7/12/2014 07:51:24,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,The occurrence of cluster headache sine HEADACHE and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,0-4-15-18-26-35-40-49-53-61-70-73-77-82-89-98-107-112-116-122-132-135-143-146-158-167-150,0-4-15-18-26-35-40-49-53-61-70-73-77-82-89-98-107-112-116-122-132-135-143-146-150-167-158,The occurrence of CLUSTER HEADACHE sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 07:55:40,,1321259031,7/12/2014 07:55:15,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,sine HEADACHE,35-40,18-26,CLUSTER HEADACHE,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 08:06:06,,1321262466,7/12/2014 08:04:32,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,HEADACHE,40,18-26,CLUSTER HEADACHE,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 08:17:00,,1321265412,7/12/2014 08:16:43,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,HEADACHE,40,18-26,CLUSTER HEADACHE,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568400,7/12/2014 08:25:27,,1321268293,7/12/2014 08:25:22,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,40,18,,,48,34,HEADACHE,CLUSTER HEADACHE,cluster headache sine HEADACHE and cluster headache,18-26-35-40-49-53-61,0-4-15-18-26-35-40-49,The occurrence of CLUSTER HEADACHE sine headache and,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome.,40,18 26,40,18,48,34,-1,RO-has_definitional_manifestation,904628,The occurrence of cluster headache sine headache and cluster headache in the same family strongly suggests that the first condition is related to the cluster headache syndrome,headache,cluster headache
502568401,7/12/2014 07:27:43,,1321250403,7/12/2014 07:26:42,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,DYSPLASIA,92,54-68,TUBULOVILLOUS ADENOMA,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 07:31:53,,1321251749,7/12/2014 07:31:24,prodege,1.0,6316959,GBR,"","",87.112.13.121,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,high grade DYSPLASIA,81-86-92,54-68,TUBULOVILLOUS ADENOMA,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 08:01:22,,1321261041,7/12/2014 08:01:06,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,high grade DYSPLASIA,81-86-92,54-68,TUBULOVILLOUS ADENOMA,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 08:33:09,,1321271165,7/12/2014 08:32:58,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,DYSPLASIA,92,54-68,TUBULOVILLOUS ADENOMA,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 08:33:13,,1321271176,7/12/2014 08:32:25,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,DYSPLASIA,92,54-68,TUBULOVILLOUS ADENOMA,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 08:47:48,,1321275502,7/12/2014 08:47:41,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,adenoma with high grade DYSPLASIA located in the,76-81-86-92-102-110-113-68,37-43-52-54-68-76-81-86-92,which revealed a TUBULOVILLOUS ADENOMA with high grade dysplasia,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 08:48:32,,1321275757,7/12/2014 08:48:09,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,DYSPLASIA,92,54-68-92,TUBULOVILLOUS ADENOMA dysplasia,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 08:57:36,,1321278726,7/12/2014 08:56:47,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,high grade DYSPLASIA,81-86-92,54-68,TUBULOVILLOUS ADENOMA,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 08:57:52,,1321278799,7/12/2014 08:57:34,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,high grade DYSPLASIA,81-86-92,54-68,TUBULOVILLOUS ADENOMA,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568401,7/12/2014 09:02:14,,1321280397,7/12/2014 08:59:32,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,92,54,,,101,75,DYSPLASIA,TUBULOVILLOUS ADENOMA,high grade DYSPLASIA,81-86-92,54-68,TUBULOVILLOUS ADENOMA,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis.",92,54 68,92,54,101,75,1,RO-disease_has_finding,901552,"A right hemicolectomy was performed, which revealed a tubulovillous adenoma with high grade dysplasia located in the ascending colon, and a diffuse ischemic colitis",dysplasia,tubulovillous adenoma
502568402,7/12/2014 07:18:47,,1321247141,7/12/2014 07:17:52,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,neurofibromatosis type 1 (NF1) - related and sporadic MPNSTS.,167-185-190-192-197-198-206-213-222,167-185-190-192-198-206-213-222,NEUROFIBROMATOSIS TYPE 1 (NF1) related and sporadic MPNSTs.,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 07:37:51,,1321253469,7/12/2014 07:37:39,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,MPNSTS.,222,167-185-190,NEUROFIBROMATOSIS TYPE 1,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 07:38:06,,1321253550,7/12/2014 07:37:40,prodege,1.0,6316959,GBR,"","",87.112.13.121,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,sporadic MPNSTS.,213-222,167-185-190-192,NEUROFIBROMATOSIS TYPE 1 (NF1),"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 07:43:37,,1321255083,7/12/2014 07:43:09,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,sporadic MPNSTS.,213-222,167-185-190,NEUROFIBROMATOSIS TYPE 1,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 07:47:55,,1321256386,7/12/2014 07:46:33,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,sporadic MPNSTS.,222-213,167-185-190-192,NEUROFIBROMATOSIS TYPE 1 (NF1),"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 07:54:13,,1321258490,7/12/2014 07:53:24,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,MPNSTS.,222,167-185-190-192-197-198,NEUROFIBROMATOSIS TYPE 1 (NF1) - related,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 08:48:26,,1321275720,7/12/2014 08:48:14,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,related and 11 sporadic MPNSTS.,206-210-213-222-198,153-161-164-167-185-190-198-206-30,"immunohistochemically, ligands in 16 NEUROFIBROMATOSIS TYPE 1 related and","PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 08:50:56,,1321276568,7/12/2014 08:50:39,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,neurofibromatosis type MPNSTS.,167-185-222,167-185-190,NEUROFIBROMATOSIS TYPE 1,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 08:54:09,,1321277545,7/12/2014 08:53:23,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,MPNSTS.,222,167-185-190,NEUROFIBROMATOSIS TYPE 1,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568402,7/12/2014 09:01:07,,1321279898,7/12/2014 09:00:35,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,222,167,,,228,191,MPNSTS,NEUROFIBROMATOSIS TYPE 1,sporadic MPNSTS.,213-222,167-185-190,NEUROFIBROMATOSIS TYPE 1,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs.",222,167 185 190,222,167,228,191,-1,RO-has_manifestation,906234,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs",MPNSTs,neurofibromatosis type 1
502568403,7/12/2014 07:35:55,,1321252988,7/12/2014 07:35:09,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,significant HYPERTENSION,189-177,228,PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 07:45:03,,1321255520,7/12/2014 07:44:44,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,189,225-228-214,suggestive of PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 07:50:21,,1321257170,7/12/2014 07:50:00,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,189,228,PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 08:04:03,,1321261845,7/12/2014 08:02:46,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,189,228,PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 08:20:07,,1321266441,7/12/2014 08:19:35,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,who have significant HYPERTENSION or symptoms suggestive,168-172-177-189-202-205-214,205-214-225-228,symptoms suggestive of PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 08:30:20,,1321270190,7/12/2014 08:30:06,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,189,228,PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 08:47:40,,1321275444,7/12/2014 08:47:33,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,who have significant HYPERTENSION or symptoms suggestive of,168-172-177-189-202-205-214-225,205-214-225-228-202,or symptoms suggestive of PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 08:55:20,,1321277956,7/12/2014 08:55:00,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,189,228,PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 08:57:08,,1321278569,7/12/2014 08:56:55,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,189,228,PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568403,7/12/2014 09:03:02,,1321280692,7/12/2014 09:02:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,189,228,,,201,244,HYPERTENSION,PHEOCHROMOCYTOMA,significant HYPERTENSION,177-189,228,PHEOCHROMOCYTOMA.,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma.",189,228,189,228,201,244,-1,RO-disease_may_have_finding,902695,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant hypertension or symptoms suggestive of pheochromocytoma",hypertension,pheochromocytoma
502568404,7/12/2014 07:29:11,,1321250931,7/12/2014 07:28:44,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,INSULIN DEPENDENT DIABETES MELLITUS,169-177-187-196,135,INSULIN,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 07:31:28,,1321251661,7/12/2014 07:30:50,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,INSULIN DEPENDENT DIABETES MELLITUS,169-177-187-196,135,INSULIN,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 07:32:16,,1321251854,7/12/2014 07:31:41,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,INSULIN DEPENDENT DIABETES MELLITUS,169-177-187-196,135-143,"INSULIN independent,","The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 07:32:57,,1321252114,7/12/2014 07:32:41,prodege,1.0,6316959,GBR,"","",87.112.13.121,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,INSULIN DEPENDENT DIABETES MELLITUS,169-177-187-196,135,INSULIN,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 07:47:10,,1321256138,7/12/2014 07:45:58,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,INSULIN DEPENDENT DIABETES MELLITUS,169-177-187-196,135-143-187-196,"INSULIN independent, diabetes mellitus","The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 07:56:41,,1321259416,7/12/2014 07:56:14,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,30 INSULIN DEPENDENT DIABETES MELLITUS,156-169-177-187-196,135,INSULIN,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 08:11:51,,1321264088,7/12/2014 08:11:06,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,dependent red cell membranes compared with INSULIN DEPENDENT DIABETES MELLITUS,61-82-86-91-106-164-169-177-187-196,118-121-130-135-143-156-159-164-169-177-187-196-205-210-218-226-229-238,"46 patients with INSULIN independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders,","The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 08:13:32,,1321264558,7/12/2014 08:13:00,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,30 INSULIN DEPENDENT DIABETES MELLITUS,156-169-177-187-196,135-143-187,"INSULIN independent, diabetes","The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 08:21:29,,1321266957,7/12/2014 08:21:18,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,30 ones with INSULIN DEPENDENT DIABETES MELLITUS with various degrees,156-159-164-169-177-187-196-205-210-218,118-121-130-135-143-156-159,"46 patients with INSULIN independent, 30 ones","The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568404,7/12/2014 08:23:45,,1321267656,7/12/2014 08:23:13,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,169,135,,,204,142,INSULIN DEPENDENT DIABETES MELLITUS,INSULIN,"kinase C, 30 ones with INSULIN DEPENDENT DIABETES MELLITUS predominant",26-33-156-159-164-169-177-187-196-298,135,INSULIN,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs.",169 177 187 196,135,169,135,204,142,1,RO-may_treat,908153,"The activities of protein kinase C, total, Mg2 and Na+, K(+)-dependent ATPases in red cell membranes were compared in 46 patients with insulin independent, 30 ones with insulin dependent diabetes mellitus with various degrees of vascular disorders, and in 17 patients with atherosclerosis with the predominant involvement of the main vessels of the lower limbs",insulin dependent diabetes mellitus,insulin
502568405,7/12/2014 07:41:44,,1321254506,7/12/2014 07:41:27,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,HYPERTENSION,65,0,NEPHROBLASTOMA,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 07:41:56,,1321254566,7/12/2014 07:41:33,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,HYPERTENSION,65,0,NEPHROBLASTOMA,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 07:43:08,,1321254957,7/12/2014 07:42:47,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,HYPERTENSION,65,0,NEPHROBLASTOMA,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 07:46:11,,1321255851,7/12/2014 07:45:50,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,HYPERTENSION,65,0,NEPHROBLASTOMA,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 08:19:31,,1321266221,7/12/2014 08:19:21,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,HYPERTENSION,65,0,NEPHROBLASTOMA,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 08:22:13,,1321267172,7/12/2014 08:22:01,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,Nephroblastoma differential diagnosis of HYPERTENSION associated with increased,39-52-62-65-78-89-94-0,0-15-20-23-65,NEPHROBLASTOMA must be included hypertension,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 08:37:12,,1321272288,7/12/2014 08:37:05,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,HYPERTENSION,65,0,NEPHROBLASTOMA,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 08:49:02,,1321275910,7/12/2014 08:48:55,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,the differential diagnosis of HYPERTENSION associated with increased,39-52-62-65-78-89-94-35,0-15-20-23-32,NEPHROBLASTOMA must be included in,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 08:50:38,,1321276451,7/12/2014 08:50:27,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,HYPERTENSION,65,0-65,NEPHROBLASTOMA hypertension,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568405,7/12/2014 08:53:30,,1321277408,7/12/2014 08:52:45,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,65,0,,,77,14,HYPERTENSION,NEPHROBLASTOMA,"HYPERTENSION associated with increased renin concentrations,",65-78-89-94-104-110,0,NEPHROBLASTOMA,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass..",65,0,65,0,77,14,1,RO-disease_may_have_finding,902706,"Nephroblastoma must be included in the differential diagnosis of hypertension associated with increased renin concentrations, even in the absence of an abdominal mass.",hypertension,Nephroblastoma
502568406,7/12/2014 07:40:14,,1321254087,7/12/2014 07:39:17,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,319--1,eosinophil in,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 08:00:03,,1321260546,7/12/2014 07:59:19,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,319,in,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 08:09:07,,1321263350,7/12/2014 08:08:30,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,,,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 08:11:36,,1321264029,7/12/2014 08:10:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,-1,eosinophil,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 08:18:49,,1321265975,7/12/2014 08:18:11,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,319--1,eosinophil in,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 08:24:54,,1321268045,7/12/2014 08:24:24,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,-1-160-319-288,eosinophil mediated T-lymphocyte-mediated in,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 08:32:18,,1321270867,7/12/2014 08:31:33,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,-1,eosinophil,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 08:49:35,,1321276081,7/12/2014 08:49:10,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,319--1,eosinophil in,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 08:55:00,,1321277813,7/12/2014 08:54:25,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,-1,eosinophil,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568406,7/12/2014 09:06:40,,1321281760,7/12/2014 09:04:36,neodev,1.0,20929875,USA,MA,Boston,71.174.188.90,222,337,,,249,344,VERNAL KERATOCONJUNCTIVITIS,ALLERGY,eosinophil,-1,-1,eosinophil,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy.",,,222,337,249,344,-1,RO-cause_of,900163,"Allergic eye diseases are characterized by IgE-mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T-lymphocyte-mediated response, as seen in giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis; or a T-lymphocyte-mediated response in contact ocular allergy",vernal keratoconjunctivitis,allergy
502568407,7/12/2014 07:30:24,,1321251307,7/12/2014 07:29:50,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,MYELOFIBROSIS,204,135-141,ACUTE MYELOFIBROSIS,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 07:30:49,,1321251454,7/12/2014 07:29:09,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,chronic MYELOFIBROSIS,196-204,135-141,ACUTE MYELOFIBROSIS,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 07:42:29,,1321254723,7/12/2014 07:42:12,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,disease while chronic MYELOFIBROSIS should be considered,182-190-196-204-218-225-228,135-141,ACUTE MYELOFIBROSIS,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 08:11:04,,1321263878,7/12/2014 08:10:09,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,acute myelofibrosis and AAMM could be same disease while chronic MYELOFIBROSIS considered a separate entity.,135-141-155-159-164-170-177-182-190-196-204-228-239-241-250,135-141-155-159-164-170-173-177-182,ACUTE MYELOFIBROSIS and AAMM could be the same disease,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 08:23:12,,1321267499,7/12/2014 08:22:59,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,myelofibrosis disease while chronic MYELOFIBROSIS should be considered,182-190-196-204-218-225-228-141,114-122-130-135-141-155-159-164-204,disease suggest that ACUTE MYELOFIBROSIS and AAMM could myelofibrosis,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 08:37:36,,1321272426,7/12/2014 08:37:26,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,chronic MYELOFIBROSIS,196-204,135-141,ACUTE MYELOFIBROSIS,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 08:40:05,,1321273137,7/12/2014 08:39:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,MYELOFIBROSIS,204,135-141,ACUTE MYELOFIBROSIS,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 08:48:47,,1321275838,7/12/2014 08:48:42,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,disease while chronic MYELOFIBROSIS should be considered a,182-190-196-204-218-225-228-239,114-122-130-135-141-155-159-164-170,disease suggest that ACUTE MYELOFIBROSIS and AAMM could be,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 08:54:24,,1321277614,7/12/2014 08:54:10,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,chronic MYELOFIBROSIS be,196-204-225,135-141,ACUTE MYELOFIBROSIS,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568407,7/12/2014 08:58:04,,1321278837,7/12/2014 08:57:37,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,204,135,,,217,154,MYELOFIBROSIS,ACUTE MYELOFIBROSIS,chronic MYELOFIBROSIS,196-204,135-141,ACUTE MYELOFIBROSIS,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity.,204,135 141,204,135,217,154,-1,RO-disease_has_finding,901527,This abnormality already demonstrated in two previous cases of acute myelofibrosis and the clinical course of the disease suggest that acute myelofibrosis and AAMM could be the same disease while chronic myelofibrosis should be considered a separate entity,myelofibrosis,acute myelofibrosis
502568408,7/12/2014 07:29:28,,1321251000,7/12/2014 07:29:09,prodege,1.0,6316959,GBR,"","",87.112.13.121,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,postural HEADACHE,2-11,33-38-45-54,POST LUMBAR PUNCTURE HEADACHE,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 07:29:48,,1321251129,7/12/2014 07:29:12,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,HEADACHE,11,33-38-45-54,POST LUMBAR PUNCTURE HEADACHE,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 07:32:23,,1321251895,7/12/2014 07:31:15,elite,1.0,28322695,GBR,G8,Dewsbury,217.44.206.25,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,postural HEADACHE,2-11,33-38-45-54,POST LUMBAR PUNCTURE HEADACHE,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 07:42:45,,1321254814,7/12/2014 07:42:13,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,postural HEADACHE,2-11,33-38-45-54,POST LUMBAR PUNCTURE HEADACHE,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 07:55:58,,1321259120,7/12/2014 07:55:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,postural HEADACHE,2-11,33-38-45-54,POST LUMBAR PUNCTURE HEADACHE,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 07:59:41,,1321260434,7/12/2014 07:59:22,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,HEADACHE,11,33-38-45-54,POST LUMBAR PUNCTURE HEADACHE,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 08:00:53,,1321260877,7/12/2014 08:00:04,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,"HEADACHE similar to a post lumbar puncture headache after sexual activity,",11-20-28-31-33-38-45-54-73-79-86,33-38-45-54-67-107-115-118-120-126-131-135-139,POST LUMBAR PUNCTURE HEADACHE occur because of a dural tear and CSF leak,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 08:12:45,,1321264340,7/12/2014 08:12:31,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,postural HEADACHE a,2-11-31,33-38-45-54,POST LUMBAR PUNCTURE HEADACHE,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 08:20:41,,1321266656,7/12/2014 08:20:40,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,A postural HEADACHE similar to a,0-2-11-20-28-31,20-28-31-33-38-45-54-63-67-73,similar to a POST LUMBAR PUNCTURE HEADACHE can occur after,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568408,7/12/2014 08:47:54,,1321275517,7/12/2014 08:47:49,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,11,33,,,19,62,HEADACHE,POST-LUMBAR PUNCTURE HEADACHE,A postural HEADACHE similar to a post,0-2-11-20-28-31-33,20-28-31-33-38-45-54-63-67-73-79,similar to a POST LUMBAR PUNCTURE HEADACHE can occur after sexual,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity.",11,33 38 45 54,11,33,19,62,-1,RO-has_definitional_manifestation,904994,"A postural headache similar to a post-lumbar puncture headache can occur after sexual activity, presumably because of a dural tear and CSF leak triggered by the activity",headache,post-lumbar puncture headache
502568409,7/12/2014 07:25:56,,1321249728,7/12/2014 07:25:40,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,141,67,,,145,76,BONE,BONE LOSS,relative to basal BONE volumes.,123-132-135-141-146,55-58-62-67-72-77-80-85-91-95,to OVX with BONE LOSS in both femur and tibia,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 07:26:41,,1321250021,7/12/2014 07:26:14,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,141,67,,,145,76,BONE,BONE LOSS,BONE,141,67-72,BONE LOSS,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 07:34:34,,1321252641,7/12/2014 07:34:20,prodege,1.0,6316959,GBR,"","",87.112.13.121,141,67,,,145,76,BONE,BONE LOSS,basal BONE,135-141,67-72,BONE LOSS,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 07:48:05,,1321256425,7/12/2014 07:47:03,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,141,67,,,145,76,BONE,BONE LOSS,BONE,141,67-72,BONE LOSS,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 07:51:26,,1321257563,7/12/2014 07:50:47,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,141,67,,,145,76,BONE,BONE LOSS,BONE,141,67-72,BONE LOSS,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 07:52:48,,1321257999,7/12/2014 07:52:25,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,141,67,,,145,76,BONE,BONE LOSS,basal BONE,135-141,67-72,BONE LOSS,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 08:13:22,,1321264507,7/12/2014 08:12:42,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,141,67,,,145,76,BONE,BONE LOSS,ITAM adapter deficient mice with bone loss relative to basal BONE volumes.,17-22-30-40-62-67-72-123-132-141-146-135,40-45-55-58-62-67-72-77-80-85-91-95-104-118-101,"mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%,","In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 08:20:19,,1321266505,7/12/2014 08:20:17,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,141,67,,,145,76,BONE,BONE LOSS,relative to basal BONE volumes.,123-132-135-141-146,55-58-62-67-72-77-80-85,to OVX with BONE LOSS in both femur,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 08:26:32,,1321268775,7/12/2014 08:26:27,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,141,67,,,145,76,BONE,BONE LOSS,relative to basal BONE volumes.,123-132-135-141-146,55-58-62-67-72-77-80-85,to OVX with BONE LOSS in both femur,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568409,7/12/2014 08:40:24,,1321273306,7/12/2014 08:40:06,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,141,67,,,145,76,BONE,BONE LOSS,BONE,141,67-72,BONE LOSS,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes.",141,67 72,141,67,145,76,1,RO-has_finding_site,905117,"In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes",bone,bone loss
502568410,7/12/2014 07:41:00,,1321254359,7/12/2014 07:40:44,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER biopsy specimen,100-106-113,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 07:48:53,,1321256684,7/12/2014 07:48:26,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER biopsy specimen,100-106-113,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 07:56:49,,1321259453,7/12/2014 07:55:34,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER,100,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 07:57:42,,1321259692,7/12/2014 07:56:33,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER biopsy specimen from patient with chronic hepatitis,100-106-113-122-129-137-142-150,142-150-160-214-221-232-237-242-251-263-268-271-284-291-300-303-309-313-321,"CHRONIC HEPATITIS includes (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline)","In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 08:03:26,,1321261668,7/12/2014 08:03:08,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER,100,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 08:16:28,,1321265285,7/12/2014 08:15:51,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER biopsy specimen,100-106-113,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 08:34:43,,1321271584,7/12/2014 08:34:29,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER biopsy specimen,100-106-113,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 08:36:57,,1321272223,7/12/2014 08:36:16,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER,100,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 08:56:24,,1321278290,7/12/2014 08:56:07,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.250,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER,100,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568410,7/12/2014 09:01:28,,1321280030,7/12/2014 09:01:09,instagc,1.0,27770607,USA,TX,El Paso,72.183.244.51,100,142,,,105,159,LIVER,CHRONIC HEPATITIS,LIVER biopsy specimen,100-106-113,142-150,CHRONIC HEPATITIS,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",100,142 150,100,142,105,159,1,RO-disease_has_primary_anatomic_site,902294,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a liver biopsy specimen from a patient with chronic hepatitis includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence",liver,chronic hepatitis
502568411,7/12/2014 07:32:27,,1321251935,7/12/2014 07:31:58,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,DYSPLASIA,122,68-77,CERVICAL DYSPLASIA,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 07:32:39,,1321252033,7/12/2014 07:32:20,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,DYSPLASIA,122,68-77,CERVICAL DYSPLASIA,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 07:39:16,,1321253878,7/12/2014 07:38:29,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,cervical dysplasia DYSPLASIA,68-77-122,68-77-122,CERVICAL DYSPLASIA dysplasia,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 07:49:37,,1321256877,7/12/2014 07:49:14,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,DYSPLASIA,122,68-77,CERVICAL DYSPLASIA,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 07:58:08,,1321259850,7/12/2014 07:57:54,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,DYSPLASIA,122,68-77,CERVICAL DYSPLASIA,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 08:13:45,,1321264592,7/12/2014 08:13:33,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,DYSPLASIA,122,68-77,CERVICAL DYSPLASIA,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 08:37:25,,1321272368,7/12/2014 08:37:14,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,DYSPLASIA,122,68-77,CERVICAL DYSPLASIA,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 08:42:26,,1321273816,7/12/2014 08:42:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,DYSPLASIA,122,68-77,CERVICAL DYSPLASIA,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 08:47:59,,1321275558,7/12/2014 08:47:55,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,change and 0.75% for DYSPLASIA and 0.84% for,108-112-118-122-132-136-142-47,54-58-64-68-77-87-93-97-47,change was 0.23% for CERVICAL DYSPLASIA among the Aborigines,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568411,7/12/2014 08:49:24,,1321276041,7/12/2014 08:49:04,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,122,68,,,131,86,DYSPLASIA,CERVICAL DYSPLASIA,cervical dysplasia DYSPLASIA carcinoma,68-77-122-146,68-77-122-146,CERVICAL DYSPLASIA dysplasia carcinoma,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group.,122,68 77,122,68,131,86,-1,RO-disease_has_finding,901851,The actual incidence of unsuspected dysplastic change was 0.23% for cervical dysplasia among the Aborigines and 0.75% for dysplasia and 0.84% for carcinoma-in-situ in the metropolitan group,dysplasia,cervical dysplasia
502568412,7/12/2014 07:31:05,,1321251527,7/12/2014 07:30:50,prodege,1.0,6316959,GBR,"","",87.112.13.121,80,4,,,95,9,POLYPOID LESION,POLYP,POLYPOID LESION,80-89,4,POLYP,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 07:32:54,,1321252089,7/12/2014 07:32:28,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,80,4,,,95,9,POLYPOID LESION,POLYP,POLYPOID LESION,80-89,4,POLYP,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 07:35:08,,1321252781,7/12/2014 07:34:48,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,80,4,,,95,9,POLYPOID LESION,POLYP,POLYPOID LESION,80-89,4,POLYP,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 07:36:40,,1321253171,7/12/2014 07:36:24,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,80,4,,,95,9,POLYPOID LESION,POLYP,POLYPOID LESION,80-89,4,POLYP,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 07:42:03,,1321254599,7/12/2014 07:41:27,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,80,4,,,95,9,POLYPOID LESION,POLYP,polyp POLYPOID LESION lymphoid hyperplasia.,4-80-89-122-131,4-22-25-122-131,POLYP at the lymphoid hyperplasia.,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 07:58:31,,1321259972,7/12/2014 07:58:09,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,80,4,,,95,9,POLYPOID LESION,POLYP,POLYPOID LESION,80-89,4,POLYP,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 08:15:20,,1321264942,7/12/2014 08:14:49,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,80,4,,,95,9,POLYPOID LESION,POLYP,microscopically both the POLYPOID LESION and the appendix lymphoid hyperplasia.,55-71-76-80-89-96-100-104-122-131,0-4-14-22-25-29-34-37-41,"The POLYP located at the base of the appendix,","The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 08:18:38,,1321265920,7/12/2014 08:18:26,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,80,4,,,95,9,POLYPOID LESION,POLYP,POLYPOID LESION appendix,80-89-104,4-14,POLYP located,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 08:20:32,,1321266610,7/12/2014 08:20:29,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,80,4,,,95,9,POLYPOID LESION,POLYP,microscopically both the POLYPOID LESION and the appendix,55-71-76-80-89-96-100-104,0-4-10-14-22,The POLYP was located at,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568412,7/12/2014 08:25:40,,1321268374,7/12/2014 08:25:34,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,80,4,,,95,9,POLYPOID LESION,POLYP,microscopically both the POLYPOID LESION and the appendix,55-71-76-80-89-96-100-104,0-4-10-14-22,The POLYP was located at,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia.",80 89,4,80,4,95,9,-1,RO-disease_has_finding,901697,"The polyp was located at the base of the appendix, and microscopically both the polypoid lesion and the appendix revealed lymphoid hyperplasia",polypoid lesion,polyp
502568413,7/12/2014 07:32:40,,1321252036,7/12/2014 07:31:53,prodege,1.0,6316959,GBR,"","",87.112.13.121,69,61,,,74,66,GISTS,GANTS,GISTS,69,33-36-47-53-60,"GI autonomous nerve tumors (GANTS),","It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 07:33:27,,1321252295,7/12/2014 07:32:24,elite,1.0,28322695,GBR,G8,Dewsbury,217.44.206.25,69,61,,,74,66,GISTS,GANTS,GISTS,69,33-36-47-53,GI autonomous nerve tumors,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 07:38:30,,1321253669,7/12/2014 07:38:11,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,69,61,,,74,66,GISTS,GANTS,GISTS,69,,,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 07:40:16,,1321254104,7/12/2014 07:39:46,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,69,61,,,74,66,GISTS,GANTS,GISTS,69,60,"(GANTS),","It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 07:45:56,,1321255786,7/12/2014 07:45:10,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.224,69,61,,,74,66,GISTS,GANTS,GISTS,69,33-36-47-53-60,"GI autonomous nerve tumors (GANTS),","It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 08:11:52,,1321264086,7/12/2014 08:11:37,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,69,61,,,74,66,GISTS,GANTS,GISTS with ultrastructural features,69-75-80-96,47-53-60-69-75-80,"nerve tumors (GANTS), GISTs with ultrastructural","It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 08:17:39,,1321265593,7/12/2014 08:17:38,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,69,61,,,74,66,GISTS,GANTS,"nerve tumors (GANTs), GISTS with ultrastructural features",47-53-60-69-75-80-96,47-53-60-69-75-80,"nerve tumors (GANTS), GISTs with ultrastructural","It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 08:42:02,,1321273725,7/12/2014 08:41:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,69,61,,,74,66,GISTS,GANTS,GISTS,69,60,"(GANTS),","It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 08:49:47,,1321276142,7/12/2014 08:49:43,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,69,61,,,74,66,GISTS,GANTS,"nerve tumors (GANTs), GISTS with ultrastructural features region.",47-53-60-69-75-80-96-221,47-53-60-69-75-80-221,"nerve tumors (GANTS), GISTs with ultrastructural region.","It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568413,7/12/2014 08:51:46,,1321276813,7/12/2014 08:51:30,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,69,61,,,74,66,GISTS,GANTS,"GI autonomous nerve tumors (GANTs), GISTS",33-36-47-53-60-69,33-36-47-53-60,"GI autonomous nerve tumors (GANTS),","It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.",69,,69,61,74,66,-1,RO-has_manifestation,906026,"It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region",GISTs,GANTs
502568414,7/12/2014 07:11:05,,1321244721,7/12/2014 07:10:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,"NEUROENDOCRINE DIFFERENTIATION of the lungs,",202-217-233-236-240,285-289-301-304-310-315,the development of SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 07:33:23,,1321252267,7/12/2014 07:32:55,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,202-217,304-310-315,SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 07:36:36,,1321253158,7/12/2014 07:36:20,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,202-217,304-310-315,SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 07:37:25,,1321253336,7/12/2014 07:36:59,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,202-217,304-310-315,SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 07:44:03,,1321255222,7/12/2014 07:43:25,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,tumours NEUROENDOCRINE DIFFERENTIATION,202-217-149,304-310-315,SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 07:54:44,,1321258748,7/12/2014 07:54:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,202-217,304-310-315,SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 07:59:00,,1321260149,7/12/2014 07:58:19,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,"NEUROENDOCRINE DIFFERENTIATION of the lungs, associated with the development of small cell carcinoma.",202-217-233-236-240-255-266-285-289-301-304-315-310,191-196-202-217-233-236-240-255-285-289-301-304-310-315-266,"gene based neuroendocrine differentiation of the lungs, associated with the development of SMALL CELL CARCINOMA.","In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 07:59:21,,1321260284,7/12/2014 07:57:53,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,202-217,304-310-315,SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 08:21:37,,1321267001,7/12/2014 08:21:05,instagc,1.0,28301350,GBR,K4,Plymouth,89.241.102.134,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,carcinogenesis NEUROENDOCRINE DIFFERENTIATION,202-217-20,20-304-310-315,carcinogenesis SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568414,7/12/2014 08:41:41,,1321273626,7/12/2014 08:41:18,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,202,304,,,232,324,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,202-217,304-310-315,SMALL CELL CARCINOMA.,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma.",202 217,304 310 315,202,304,232,324,-1,RO-disease_has_finding,901816,"In investigation on carcinogenesis the first reports were published on the use of antisense-oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene-based neuroendocrine differentiation of the lungs, perhaps associated with the basis for the development of small cell carcinoma",neuroendocrine differentiation,small cell carcinoma
502568415,7/12/2014 07:32:18,,1321251867,7/12/2014 07:31:48,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.2.200,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,NEPHROPATHY,23,79-85,DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 07:34:59,,1321252766,7/12/2014 07:34:44,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,NEPHROPATHY,23,79-85,DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 07:36:22,,1321253110,7/12/2014 07:35:57,prodege,1.0,6316959,GBR,"","",87.112.13.121,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,NEPHROPATHY,23,68-79-85,incomplete DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 07:37:12,,1321253290,7/12/2014 07:36:40,clixsense,1.0,6344740,USA,WA,Longview,71.193.162.200,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,NEPHROPATHY,23,79-85-68,incomplete DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 08:08:33,,1321263180,7/12/2014 08:07:58,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete Drash syndrome.,0-8-19-23-35-39-45-63-68-79-85,0-8-19-23-45-79-85-63,Gonadal dysgenesis and nephropathy indistinguishable from DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 08:18:53,,1321265994,7/12/2014 08:18:50,neodev,1.0,11598752,CAN,ON,Toronto,216.165.208.242,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable,0-8-19-23-35-39-45,45-63-68-79-85,indistinguishable from incomplete DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 08:22:31,,1321267270,7/12/2014 08:22:14,neodev,1.0,11051762,NLD,09,Utrecht,87.212.164.10,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable Drash,0-8-19-23-35-39-45-79,0-8-45-63-68-79-85-23,Gonadal dysgenesis nephropathy indistinguishable from incomplete DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 08:30:49,,1321270386,7/12/2014 08:30:40,clixsense,1.0,6355977,NLD,07,Amsterdam,46.129.42.165,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,NEPHROPATHY,23,79-85,DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 08:46:19,,1321274914,7/12/2014 08:46:15,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from,0-8-19-23-35-39-45-63,45-63-68-79-85-39,often indistinguishable from incomplete DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
502568415,7/12/2014 08:53:45,,1321277458,7/12/2014 08:53:31,neodev,1.0,26698025,NLD,05,Kerkrade,84.25.162.122,23,79,,,34,93,NEPHROPATHY,DRASH SYNDROME,Gonadal dysgenesis and NEPHROPATHY,0-8-19-23,79-85,DRASH SYNDROME.,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome.,23,79 85,23,79,34,93,-1,RO-has_manifestation,906144,Gonadal dysgenesis and nephropathy are often indistinguishable from incomplete Drash syndrome,nephropathy,Drash syndrome
